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Thesis summary  
Aston University, The Development of Affinity Aqueous Two Phase Systems as a 
Method of Purifying Therapeutic Proteins, Jennifer Elizabeth Lines, Master of 
Philosophy, 2015. 
 
Aqueous two-phase systems (ATPS) are formed when two immiscible and physico-
chemically disparate polymers, such as poly(ethylene) glycol (PEG) and dextran (DEX), 
are mixed in water. Full explanations of the precise physical and chemical mechanisms 
of phase separation and macromolecule partitioning have yet to be described causing 
the prediction of macromolecule behaviour to be difficult. A systematic analysis of 
multiple 20% w/v PEG and DEX combinations was performed at room temperature in 
order to determine which formed two distinct phases with both purified green fluorescent 
protein (GFPuv) and E.coli Tuner (DE3) cell lysate containing GFPuv. All layers were 
checked for the presence of protein, DNA and RNA using fluorescence, Bradford assay 
and ethidium bromide staining of 1% agarose gels. The formation of two distinct layers 
occurred in 45% of combinations and preferentially when both PEG and DEX were of a 
higher molecular weight. All ATPS formed showed complete partitioning of genomic 
material to the lower phase and 60% showed complete partitioning of proteins and cell 
debris to the bottom phase or interface. It was also determined by fluorescence that 
100% of GFPuv partitioned to the lower phase in all ATPS. As determined from previous 
screening, select ATPS combinations were formed using PEGylated glutathione and 
GST-fused GFPuv. Experimentation progressed onto using cell lysates containing 
histidine-tagged GFPuv and PEGylated nitrilotriacetic acid (NTA). Protein partitioning 
was analysed using Bradford assay and SDS-PAGE. PEG phase partitioning of GFPuv 
can be seen when 1% of overall PEG is functionalised. These results show that the 
partitioning of GFPuv is not dependent upon the presence of cell debris and will allow 
for quicker selection of PEG and DEX molecular weight combinations. The results will 
also allow further development of the system into a generic affinity purification method 
using PEGylated NTA with coordinated copper ions as a ligand for histidine tagged 
proteins. 
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Chapter 1. Introduction  
 
Therapeutically relevant proteins are required in increasing quantity for a wide 
number of applications ranging from new drug discovery, recombinant protein production 
and high-throughput screening on a research level to the development and production 
of proteins of pharmaceutical importance on an industrial scale (Saraswat et al., 2013). 
Whilst many of the shortcomings of the upstream processes have been addressed 
already in recent years, with areas such as cell culture being improved to the point that 
recombinant protein yields have increased almost a thousand fold to tens of grams per 
litre (Gottschalk, 2008). With such high yields now achievable the purification process 
can be considered a highly labour intensive part of the process at the same time as 
incurring high production costs, in some cases the cost of downstream processing can 
range between 50 % and 80 % of the total cost of manufacture (Lowe, 2001). This has 
resulted in traditional downstream processing techniques, such as affinity 
chromatography, being considered too costly, as well as time consuming and not 
capable of processing these higher quantities within a reasonable time frame.  
At present, a common method for large scale purification of therapeutically 
relevant proteins after harvesting, by using a method such as centrifugation or sterile 
filtration, is a number of affinity column chromatography steps followed by a viral filtration 
method. This can then be followed by an ultrafiltration / diafiltration stage in order to 
obtain a product that is concentrated in the required final buffer and pure enough for 
therapeutic use (Trexler-Schmidt et al., 2009). There must also be a large enough 
quantity of the purified protein in both industrial and research scale productions in order 
to test the efficacy, structural integrity and resulting activity of the protein. There are 
various constraints associated with these methods, such as the high cost of resins and 
buffers, which have a limiting effect on the volumes able to be processed. In addition, 
high volume columns can incur problems such as hysteresis and edge-effects where 
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different flow rates are achieved across the column due to uneven resin packing. Resin 
compression can also reduce porosity, and therefore decrease the pressure across the 
column (P. A. J. Rosa et al., 2010). These problems are also observed at laboratory 
bench scale, leaving a gap for investigation into a cost effective, generic affinity 
purification process that does not utilise column chromatography.  
Accordingly, a systematic review of the literature was performed to determine 
whether there was a gap in common knowledge that may be filled by further laboratory 
based research into the area. The aim of the following review is to identify whether the 
proposed development of affinity based aqueous two phase systems (ATPS) for the 
purification of therapeutic proteins is not only conceptually possible, but also laboratory 
feasible and commercially practicable.  
The databases searched were ISI Web of Knowledge, Science Direct and 
Google Scholar using the following search terms – aqueous two phase*, ATPS, PEG, 
dextran, DEX, phase separation, protein purification, large scale, affinity ATPS, protein 
purification medicine, protein purification biotechnology and affinity purification. Articles 
that were published after 1990 were preferentially chosen with the exception of pertinent 
original research relevant to the area such as works by the author Albertsson which are 
relevant to the original development of ATPS. 
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1.1  Current Purification Methods 
 
The methods employed to purify proteins can be broadly separated into two 
different types – affinity methods and chromatography methods. In this section both 
types of methods will be investigated into their current use in protein purification. The 
first group of methods described here are affinity based protein purification protocols. 
One of the preferred methods for the purification of therapeutically relevant proteins is 
affinity column chromatography due to its high resolving power, capacity and recovery 
(Waites, 2001). There are four main types of system which can be employed - 
polyhistidine tags that bind to metal ions; enzyme fusions that bind to immobilised 
ligands; antibody-antigen interactions and bacterial receptors that bind to serum proteins 
(Nilsson et al., 1997).  
Polyhistidine tags were first demonstrated in 1975 (Chaga, 2001) and have since 
become known as immobilised metal ion affinity chromatography (IMAC). IMAC is 
possible as the imidazole groups of the polyhistidine tag on either the C or N terminal of 
the protein will bind selectively to the metal ions available, such as nickel, copper and 
zinc. The metal ion is coordinated to the substrate via a linker and metal ion coordinating 
group such as iminodiacetic acid (IDA) or nitrilotriacetic acid (NTA). The protein is then 
eluted by lowering the pH, causing protonation of the imidazole groups, or introducing 
competition for the binding sites using imidazole. High protein recovery and purity make 
this a popular method, especially at research level however, the purity can be affected 
by non-specific binding of proteins containing external histidines in the tertiary structure. 
The IMAC methodology has become common practice when purifying proteins that 
aggregate into inclusion bodies as purification can occur under denaturing conditions 
and the protein can subsequently be refolded before elution (Rogl et al., 1998). In 
addition to this, IMAC can be modified and used to purify certain antibodies by first using 
a recombinant his-tagged antigen that binds to the substrate, which can then bind the 
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bio-active antibodies to be purified (Casey et al., 1995). However, there are 
disadvantages to this purification method since the metal chelates used to bind the metal 
ions to the substrate can be used for site specific cleavage of proteins, which potentially 
reduces the yield (Gaberc-Porekar & Menart, 2001). Another problem that can occur is 
the leaching of the metal ions, of which nickel compounds are known to be carcinogens, 
rendering the products unsuitable for pharmaceutical use (Kasprzak et al., 2003). Ni-
NTA resins are commercially available through a number of companies such as Qiagen 
who provide instructions to regenerate the resin enabling more than one purification step 
with each aliquot. This allows for the reduction in costs for the purification step on a 
laboratory bench scale, nevertheless, the regeneration and reuse of the Ni-NTA resin 
may not be suitable for industrial purification due to the potential for cross contamination. 
An additional drawback for the up scaling of this process is the high cost of the metal ion 
as well as the resin used to pack the column. Such large volumes would be required that 
not only would the costs be large, but other effects can occur such as edge hysteresis 
reducing the efficiency of purification. His-tag purification of recombinant proteins, whilst 
inherently useful for research level purposes, may not be a first port of call for industrial 
use due to the requirement of a final protein with no additional C- or N- terminal products. 
A protease able to digest the his-tag away from the required protein would be necessary 
which adds an additional digestion and purification step to the process increasing not 
only the time necessary but also the cost of manufacture.    
Recombinant proteins that are fused to enzymes such as Glutathione-S-
transferase (GST) are also successfully purified by using an immobilised ligand, in this 
case glutathione to which GST has a high specificity and affinity (H.M. Chen et al., 1999). 
GST vectors have now been designed to allow the fusion to occur at either the N- or C- 
terminal of the desired protein; this is particularly useful as some proteins have terminals 
that may be involved in protein folding (Aatsinki & Rajaniemi, 2005). Once the GST-
Protein fusion has bound to the column it can be eluted competitively using reduced 
glutathione, but this can be disadvantageous since reduced glutathione can affect the 
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disulfide bonds contained within the protein that is being purified, preventing it from 
folding properly (Chakravarthi et al., 2006). When the GST-protein fusion is made, a 
cleavage site is engineered in to allow for the easy removal of the GST. The site specific 
protease is often itself developed with an affinity tag fusion in order to allow a further 
step of affinity purification to occur, and therefore a pure product (Arnau et al., 2006). 
GST-protein fusions have also been shown to be able to be renatured if inclusion bodies 
are formed (Nguyen et al., 1996). GST fusion proteins have been shown to be able to 
be produced in large batch quantities (Korf, U et al, 2005), however, the drawbacks to 
this method arise when harvesting the fusion protein from solution. Similarly to Ni-NTA 
and his-tag purification, a large quantity of immobilising substrate is required which can 
prove costly and have a reduced efficiency.  
Maltose binding protein (MBP) is a bacterial protein that is used in a similar 
fashion to GST for affinity purification. MBP specifically binds maltose or maltodextrins 
in the periplasmic space in order for the transport and catalysis of these sugars to occur 
across the cytoplasmic membrane (Shuman, 1982). Once the MBP fusion, constructed 
with a protease cleavage site to allow for removal, has bound onto the cross linked 
amylose resin, competitive elution can occur by submitting the column to high 
concentrations of maltose (Srinivasan & Bell, 1998). This method is particularly useful 
as the conditions used are mild and because the MBP does not contain any cysteine 
residues which could interfere with the fused protein’s disulfide bonds and therefore 
folding abilities. In fact, MBP has been shown to be effective at promoting the solubility 
of the protein that it is fused to (Kapust & Waugh, 1999).  
Protein A contains a binding site for the Fc region of mammalian immunoglobulin 
G (IgG) and, when bound to a substrate, has been established as a method of affinity 
purification within both the pharmaceutical industry and at research level, especially 
during the production of antibodies and specifically monoclonal antibodies (mAbs). It is 
widely acknowledged for its high resolving power resulting in elutions with a high degree 
of purity although additional polishing purification steps may be necessary to remove 
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any impurities such as leached Protein A to render the product suitable for use (Liu et 
al., 2010). Commercially available Protein A resins such as Mabselect available from GE 
Healthcare Life Sciences are able to withstand tough conditions, especially when using 
harsh cleaning-in-place (CIP) methods, and the ability to harvest mAbs from clarified 
lysate directly. These commercially available systems range from small, laboratory 
bench scale up to industrial scale allowing for effective upscaling of production.       
(http://www.gelifesciences.com/gehcls_images/GELS/Related%20Content/Files/13148
23637792/litdoc11001159_20130905164352.PDF, Accessed 17/01/15). The long 
usable lifetime of the resin makes this method attractive when a reduction in costs is 
important; however the narrow scope of its application is limited to the purification of IgG 
only therefore it cannot be a generic process. The limitation with all of these affinity 
column chromatography methods is the high cost of resin as well as a limit to the volume 
of supernatant that can be applied at that point in time. This causes these methodologies 
to still create a bottleneck in the downstream processing of therapeutic proteins (Porath, 
J. 1992).   
Other chromatographic methods that can be used to purify proteins are available 
but lack one or more of the essential characteristics mentioned previously. Ion-exchange 
chromatography (IEX) can be used to purify proteins with a known overall charge, which 
can interact with a covalently bonded anionic or cationic functional group. IEX is often 
employed when a protein is produced without an affinity tag and high resolutions are 
achievable with the correct pH binding buffer for the overall charge of the protein. To 
allow for the removal of cellular deoxyribonucleic acid (DNA), anion exchange 
chromatography is preferentially selected after a lysate clearing protocol for removing 
cellular debris and contaminants. The protein can then be eluted from the column by 
changing the ionic concentration or altering the pH of the mobile phase. Two main 
disadvantages to this method are that only a small volume can be loaded onto the 
column initially, and a concentration step must be performed in order to utilise the 
molecule once it has been eluted. This can lead to high concentrations of residual salts 
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in the solution rendering the protein unsuitable for therapeutic use without an additional 
buffer exchange step (Aguilar, 2004). Additional costs and time are incurred as the lysate 
clearing step is required prior to IEX being used in order for the method to be effective.   
Gel filtration, or size exclusion chromatography (SEC), is a chromatographic 
purification method that filters proteins based on size as they pass through porous beds 
at different speeds. Smaller proteins travel through the beads and therefore spend a 
longer amount of time on the column than a larger protein that does not pass within the 
resin. To establish an accurate time course of proteins eluted due to size a long column 
and slow flow rates are necessary which once again increase the time and costs required 
for purification. In comparison to other methods previously described, SEC has a low 
resolution which can be widely affected by the choice of resin composition and pH of the 
mobile phase. SEC can only be employed when a pure and undiluted product is not 
required as there is an absence of specificity. This method can however be useful when 
employed after IEX as a polishing step due to its ability to desalt protein containing 
buffers. In order to desalt these buffers, water is applied to the SEC resin, that has been 
pre-equilibrated with water, allowing for proteins to pass quickly around the resin beads 
whilst the salts are delayed flowing through pores present in the resin beads (Hagel, 
1998).  
Chromatography methods are not always employed for protein purification. For 
example, acetone can be used to precipitate proteins from a solution, but any residual 
acetone may cause unwanted modifications in the protein (Simpson & Beynon, 2010). 
Another non chromatographic method is the use of magnetic beads which can be placed 
directly into the solution. These beads are composed of iron coated in a polymer that 
has a specific affinity ligand on the surface, and once bound with the protein they can be 
removed from the original solution using a magnet. This method negates the need for 
columns and centrifugation, which reduces the time and cost involved (Smith, 2005). 
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1.2  Aqueous Two-Phase Systems  
 
Within organic chemistry liquid – liquid extraction, more generally referred to as 
solvent extraction, is a common methodology employed for the partitioning of a desired 
compound from any unwanted compounds using two liquid, immiscible solvents. 
Examples of compounds that are separated using solvent extraction can include 
aromatic compounds from within crude oil fractions and vitamins required from aqueous 
solutions (Gunt, 2015). When two organic solvents or an organic solvent and water are 
used to form the two phases for particle partitioning, the shear forces produced across 
the interface are high. These forces render a solvent based extraction redundant when 
being considered in the biotechnology industry for the partitioning of molecules such as 
proteins which need to maintain the essential secondary and tertiary structures in order 
to maintain function. To overcome this, the organic solvents can be replaced with 
aqueous solutions that are immiscible and therefore the forces experienced by the 
proteins are reduced when being partitioned across the interface.  
In 1896, Beiherinck first observed the formation of Aqueous Two-Phase Systems 
(ATPS) when he combined liquid solutions of gelatin and agar; this was also the case 
when he mixed solutions of gelatin and starch. These observations have been the 
foundations of over a century of research into the mechanisms of phase separation and 
macromolecule partitioning phenomena, of which a full explanation is presently elusive. 
It is understood that ATPS are formed when two immiscible and disparate polymers, 
such as poly (ethylene) glycol (PEG) and dextran (DEX), or a polymer and a salt solution, 
are mixed in water. Due to the differing natures of the polymers, for example molecular 
weight and external polarities, two phases develop as there is a slight difference in water 
density between the layers (Albertsson, 1971). PEG and DEX ATPS were first described 
by Albertsson in 1958 and have since been the subject of much investigation, with 
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systems being described for the partitioning of many materials such as DNA (Barbosa 
et al., 2008), proteins (Rosa et al., 2007) and entire cells (Edahiro et al., 2005). 
The biotechnology industry has been increasing research in the ATPS area with 
a high interest in counter current chromatography (CCC) development due to the ability 
to have continuous separation. This is advantageous at an industrial scale as a reduction 
in time and material wastage, usually associated with batch purification, is seen. 
However, for the purposes of the researcher, CCC is likely to be costly and excessive 
for their needs. Therefore, a generic batch ATPS formed using a stationary separation 
methodology is beneficial on a smaller scale. 
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1.3  Affinity-Based Aqueous Two-Phase Systems 
 
Considering how effectively affinity purification is used in other applications, it is 
surprising that there are not more reports of it being used in conjunction with ATPS. In 
2010, Barbosa et al., reported affinity purification of plasmid DNA, by using a DNA 
binding fusion protein that was affinity bound using a His6 tag to a PEG-iminodiacetic 
acid (IDA)-Cu2+. This dual affinity directs the complex to the PEG top phase out of a 
crude cell lysate ready for a second step in order to further purify the plasmid DNA away 
from the affinity complex. This PEG-IDA-Cu2+ system has also been explored for the 
partitioning of erythrocytes which have metal binding sites on the cell surface (Goubran 
Botros et al., 1991). 
Affinity ATPS (Af-ATPS) have also been used to purify proteins by a number of 
methods. One of these was the partitioning of Immunoglobulin G (IgG) using PEG 
functionalised with glutaric, amino and benzyl groups. The authors determined that the 
most effective ligand was diglutaric acid (PEG-COOH) with an extraction of 97 % of IgG 
into the PEG phase (Azevedo et al., 2009). This method also allowed the authors to 
achieve a high percentage of 94 % purity of IgG from other proteins. An affinity tagged 
green fluorescent protein (GFPuv) has also been partitioned in an ATPS from a clarified 
E.coli cell lysate using a micellar system. This system used decyl β-D-glucopyranoside 
(C10G1) as a surfactant which formed micelles and had affinity for the novel tag attached 
to the GFPuv (Mazzola et al., 2006). Another example is shown by Fong et al., in 2002 
where an Fv antibody fragment was conjugated with a thermo separating polymer in 
order to partition hen egg white lysozyme (HEL). The authors showed that this method 
removed 80 % of the HEL from the solution. In order to partition glucose-6-phosphate 
dehydrogenase (G6PDH) and hexokinase to the top phase of a PEG / hydroxypropyl 
starch system, Xu and co-workers added free triazine dyes as affinity ligands (Xu et al., 
2003). It was found that the dye / enzyme complexes preferentially partitioned to the top 
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PEG layer and enabled the authors to further develop this system into a two stage 
extraction process for G6PDH.  
Human acute myeloid lymphoma cells that are CD34+ can also be separated 
from human T lymphoma cells using Af-ATPS. This is due to the antibody anti-CD34 
being conjugated to a temperature sensitive polymer which was added to the PEG / DEX 
ATPS and then the polymer / cell complex was precipitated out of the top PEG layer by 
heating to 32 ºC (Kumar et al., 2001).  
If further developed into a generic, rather than a specific process, Af-ATPS has 
the potential to revolutionise the downstream processing that is commonplace in 
research and industry. Some of the advantages are that the ATPS environment, 
including the interface, is very mild and therefore does not denature the product, 
resulting in higher yields (Albertsson et al., 1990). It can also be significantly more cost 
effective than column chromatography as alternative polymers to DEX, such as 
hydroxypropyl starch, have been studied and could potentially be scaled up to be a 
cheaper and more time-efficient processing method for large volumes of product 
(Tjerneld et al., 1986). 
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1.4  Up Scaling 
 
The ability to upscale protein purification methods has been investigated for many 
years. There is currently a bottle neck present in the downstream process of purification 
as large volumes of protein are able to be produced in large fermentation vats. Properties 
that make ATPS an attractive methodology for upscaling are the speed at which 
purification can be performed, attracting lower costs than chromatographic methods and 
promising high yields and purities (Kaul,R.H, 2011). When compared to Protein A 
purification, affinity ATPS is shown very favourably as having the ability to not only 
continuously purify mAbs but also a reduction in costs and environmental impact (Rosa, 
P.A.J. et al., 2011).  
It has been suggested by Gupta and co-workers that the importance for ATPS 
development on a large scale is increasing in industry and research due to the high cost 
and poorer yields of existing downstream processing techniques (Gupta et al., 1999). 
Even though the up-scaling of ATPS is reported to be simple and could address the 
issues associated with the techniques being used at the moment, there are surprisingly 
few examples in the literature demonstrating any research into this area. It was recently 
shown that PEG / salt ATPS could be formed within flexible blood bags, allowing for the 
partitioning of human serum albumin (HSA) (Garza-Madrid et al., 2010). The authors 
found that there was no impact on the partitioning behaviour of HSA caused by forming 
the ATPS in blood bags, and recovered 85% of the HSA in the top layer. They also 
demonstrated that the ATPS had a short equilibrium time of less than 6 minutes in the 
absence of centrifugation. Although using a PEG-salt system has shown to be effective 
in this case, salt is not always an ideal phase component due to increasing the interfacial 
tension between the two layers. The high salt environment can also be considered to be 
harsh for many therapeutic proteins causing them to denature before they can be purified 
for use.   
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In addition to the aforementioned studies, virus like particles (VLP) have been 
partitioned using a 500 ml multistage ATPS based on a centrifugal partitioning chromatic 
device (Effio et al., 2015). This multistage system allowed for improved partitioning of 
the VLP from host cell proteins (69.1% purity when analysed using HPLC), albeit with a 
reduced yield of 40.1% VLP recovery when compared to the single stage ATPS where 
100% VLP recovery was detected using HPLC. This methodology was not as successful 
as the previous blood bag example when comparing yields and purities but also required 
specialist equipment in order to produce continuous purification. This would increase the 
cost of each purification for a reduced yield and purity of therapeutic protein.  
Furthermore, there has been research into the recovery of prion proteins (PrP) 
from crude feedstocks that are derived from homogenated bovine brain tissue; the 
presence of which has been associated with transmissible spongiform encephalopathies 
such as BSE (Walker et al., 1996). An ATPS that contained a thermo-separating polymer 
has been shown to work at a volume of 500 L and a total recovery of 71 % of recombinant 
cutinase (Kepka et al., 2003). The feasibility of up-scaling was further shown using a 
detergent based ATPS at a volume of 2000 L (Selber et al., 2004), suggesting that it will 
be possible with other systems. Further investigation into suitable phase forming 
polymers can be done in order to reduce the costs associated. A number of examples 
have been suggested for use instead of dextran, which carries a higher cost than PEG, 
such as PVA, starch derivatives and ethyl hydroxyls. The ability to recycle many of the 
constituent polymers was also demonstrated when using the thermos regulated 
polymers (Li & Cao, 2010). 
More recently, the scaling up of an ATPS system by 850x has been described by 
Ruiz-Ruiz et al., in 2013. The authors describe the production and purification of ß-
phycoerythrin from lab bench scale to pilot plant facilities. In this instance, however, an 
amalgamation of strategies were implemented in order to purify the protein including 
isoelectric precipitation, ATPS and ultrafiltration. The final yield was reported to be 54% 
with a final purity of 4.1 under optimal conditions. This demonstrates that there is a need 
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for further research into a generic large scale ATPS to fill this gap present in the 
literature.  
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1.5  Project Outline 
 
In conclusion, the need to generate a generic Af-ATPS is becoming ever more pressing 
due to the high costs, long processing times and low yields of current solid/liquid affinity 
chromatography strategies. Therefore, the development of a new methodology would be of 
great benefit to both research and industry. Accordingly, the following plan of experimentation 
was devised. 
 
• Initial formation of ATPS. 
o Differing combinations of PEG and DEX molecular weights were 
assessed to determine which formed two distinct phases. 
o The effect on ATPS formation and protein partitioning of both the 
settling and centrifugation methods were compared to find the optimal 
methodology.  
o The behaviours of purified GFPuv and GFPuv containing cell lysate in 
PEG / DEX ATPS were also analysed to determine the influence of cell 
debris upon protein partitioning within ATPS.  
• ATPS optimisation of phase compositions. 
o The concentration and molecular weight of PEG and DEX was 
systematically analysed to find the optimal phase compositions for both 
distinct phase formation and protein partitioning.  
• PEG-Glutathione based affinity to the upper PEG phase of ATPS. 
o PEGylation of glutathione (GSH) was performed at Polytherics for use 
within the novel affinity ATPS. 
o A glutathione s-transferase (GST) tagged protein was engineered as an 
exemplar for use within the novel affinity ATPS.  
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• PEG-Nitrilotriacetic acid-Cu2+ based affinity to the upper PEG phase of ATPS. 
o PEGylation of Nitrilotriacetic acid (NTA) was performed at both UCL and 
Aston University for analysis of its suitability for use within the novel 
affinity ATPS.  
o A Histidine tagged (His6) protein was engineered as an exemplar for 
use within the novel affinity ATPS.                                   
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Chapter 2. Materials and Methods 
 
This chapter will provide all materials and methods utilised in the development of aqueous 
two phase systems as a method of purifying therapeutic proteins. Unless otherwise stated, all 
experiments were performed in triplicate in order to show repeatability. When analysing the 
results produced in this study, quantitative statistical analysis was not performed due to the 
formation of two phases being visual and replicated being identical. quantitative or descriptive 
statistical analysis was not performed.  
 
 
2.1 Media Recipes 
 
(2.1.1) Luria Bertani Broth 
Luria Bertani (LB) Broth Powder (Sigma-Aldrich) at a concentration of 20 g/L was 
dissolved into H2O and sterilised by autoclaving at 121°C for 20 minutes. If a selective culture 
was required sterile Ampicillin solution (2.2.3) or sterile Kanamycin solution (2.2.4) was added 
to cooled media (<50°C) to a final concentration of 50 µg/ml. 
 
(2.1.2) Luria Bertani Agar  
Luria Bertani (LB) Broth Powder (Sigma-Aldrich) was dissolved at a concentration of 
20 g/L in H2O with the addition of Bacto Agar (DIFCO) at 20 g/L and sterilised by autoclaving 
at 121°C for 20 minutes. If selective media was required sterile Ampicillin solution (2.2.3) or 
sterile Kanamycin solution (2.2.4) was added to cooled media (<50°C) to a final concentration 
of 50 µg/ml. 
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2.2 Buffer Recipes 
 
(2.2.1) Tris-Acetate-EDTA Buffer (TAE) 
50 x stock solution was made containing 2 M Tris-acetate and 0.05 M EDTA at pH 8.0. 
1 x TAE was prepared by dilution in double distilled H2O. 
 
(2.2.2) Loading Buffer 
30% (v / v) Glycerol, 0.025% (w / v) Xylene cyanol and double distilled H2O. 
 
(2.2.3) Ampicillin Solution 
Stock solutions were prepared using double distilled H2O and Ampicillin Sodium Salt 
(Sigma-Aldrich). The solution was then filter sterilised using a 0.2 µm syringe filter (Nalgene). 
 
(2.2.4) Kanamycin Solution 
Stock solutions were prepared using double distilled H2O and Kanamycin Sulfate 
(Sigma-Aldrich). The solution was then filter sterilised using a 0.2 µm syringe filter (Nalgene). 
 
(2.2.5) Phosphate Buffered Saline (PBS) 
PBS was prepared by dissolving one PBS tablet (Invitrogen) into 200 ml distilled H2O 
yielding 0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, 
pH 7.4, at 25 °C. This was then sterilised by autoclaving at 121°C for 20 minutes. 
 
(2.2.6) Calcium Chloride (CaCl2) Solution 
CaCl2 stock solution (50mM) was made by combining double distilled H2O with 
CaCl2.2H2O followed by a filter sterilisation step using a 0.2 µm syringe filter (Nalgene). 
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(2.2.7) Bradford Reagent 
Bradford Reagent was obtained from Bio-Rad Laboratories Inc., and prepared by 
diluting 1 part Bradford Reagent to 4 parts distilled H2O. This solution as then filtered through 
filter paper before use in methods (2.7.14) and (2.3.15). 
 
(2.2.8) Bovine Serum Albumin (BSA) Stock Solution 
A stock solution of BSA at a concentration of 1mg/ml was prepared in double distilled 
water and aliquots frozen at -20°C to be used to prepare standard curves for the Bradford 
assay. 
 
(2.2.9) Lysis Buffer 
 A stock solution was prepared containing 50 mM NaH2PO4 (Sigma-Aldrich), 300 mM 
NaCl (Sigma-Aldrich), 10 mM imidazole (Sigma-Aldrich) and the pH adjusted to 8.0 using 
NaOH. The solution was then filter sterilised using a 0.2 µm syringe filter (Nalgene). 
 
(2.2.10) Wash Buffer 
 A stock solution was prepared containing 50 mM NaH2PO4 (Sigma-Aldrich), 300 mM 
NaCl (Sigma-Aldrich), 20 mM imidazole (Sigma-Aldrich) and the pH adjusted to 8.0 using 
NaOH. The solution was then filter sterilised using a 0.2 µm syringe filter (Nalgene). 
 
(2.2.11) Elution Buffer 
A stock solution was prepared containing 50 mM NaH2PO4 (Sigma-Aldrich), 300 mM 
NaCl (Sigma-Aldrich), 250 mM imidazole (Sigma-Aldrich) and the pH adjusted to 8.0 using 
NaOH. The solution was then filter sterilised using a 0.2 µm syringe filter (Nalgene). 
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(2.2.12) Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
1 M stock solutions were prepared using double distilled water and then filter sterilised 
using a 0.2 µm syringe filter (Nalgene) and aliquots stored at -20°C. 
 
(2.2.13) PEGylation Reaction Buffer 
This buffer was prepared using 50 mM NaH2PO4 (Sigma-Aldrich), 10 mM EDTA 
(Sigma-Aldrich) and the pH adjusted to 7.8. The solution was then filter sterilised using a 0.2 
µm syringe filter (Nalgene). 
 
(2.2.14) Sodium Phosphate Buffer for PEG Maleimide Conjugation 
This buffer was prepared using 50 mM NaH2PO4 (Sigma-Aldrich), 10 mM EDTA 
(Sigma-Aldrich) and the pH adjusted to 6.0. The solution was then filter sterilised using a 0.2 
µm syringe filter (Nalgene). 
 
(2.2.15) ATPS Phosphate Buffer 
This buffer was prepared using 10 mM NaH2PO4 (Sigma-Aldrich) and the pH adjusted 
to 8.0. The solution was then filter sterilised using a 0.2 µm syringe filter (Nalgene). 
 
(2.2.16) Sodium Acetate Buffer pH 4.0 
Solution A was prepared by diluting 11.55 ml glacial acetic acid (Sigma-Aldrich) per 
litre of H2O. Solution B was prepared by dissolving 27.2 g sodium acetate (Sigma-Aldrich) per 
litre of H2O. An aliquot of solution A (41 ml) was added to 9 ml of solution B to produce a 0.1 
M buffer solution that is adjusted to pH 4.0. 
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 (2.2.17) Tris pH 9.0 Conjugation Buffer 
This buffer was prepared using 20 mM Tris (Sigma-Aldrich) and the pH adjusted to 
9.0. The solution was then filter sterilised using a 0.2 µm syringe filter (Nalgene). 
 
(2.2.18) 10 x Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS 
PAGE) Running Buffer 
A 1 litre stock solution of 10 x Running Buffer was prepared using 30 g Tris, 144 g 
Glycine and 10 g SDS in distilled H2O. When necessary this was diluted in distilled H2O to 
produce a working 1 x buffer solution.  
 
(2.2.19) 4 x Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS 
PAGE) Sample Buffer 
The protein sample buffer was produced by combining 20 ml 0.5 M Tris (pH 6.8), 20 
ml glycerol, 2 g SDS, 20 mg Bromophenol Blue and 2 ml β-mercaptoethanol.  
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2.3 Plasmid DNA 
 
(2.3.1) pGFPuv 
pGFPuv was obtained from Clontech Laboratories Inc. Oligonucleotides described in 
section (2.4.1) and (2.4.2) were used to amplify the gene encoding Green Fluorescent Protein 
(GFPuv) out of this plasmid with the required restriction enzyme sites for insertion into fusion 
plasmids.   
 
(2.3.2) pGFPuv1KL4 
pGFPuv1KL4 was very kindly donated by Dr David Nagel, Aston University. 
Oligonucleotides described in section (2.4.1) and (2.4.2) were used to amplify the gene 
encoding Green Fluorescent Protein (GFPuv) out of this plasmid with the required restriction 
enzyme sites for insertion into fusion plasmids.   
 
2.4 Oligonucleotides 
 
(2.4.1) GFPuv SmaI Blunt 
5’ CCCGGGTTATGAGTAAAGGAGAAGAAC 3’ obtained from Eurofins MWG Operon. 
Double distilled H2O was added and the solution to obtain a final concentration of 100 pmoles 
/ µl and mixed by vortex for 10seconds. The solution was then mixed on a flat rollerbed for 10 
minutes before being stored at -20 ºC. 
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(2.4.2) GFPuv EcoRI 
5’ GAATTCATTATTTGTAGAGC 3’ obtained from Eurofins MWG Operon. Double 
distilled H2O was added and the solution to obtain a final concentration of 100 pmoles / µl and 
mixed by vortex for 10seconds. The solution was then mixed on a flat rollerbed for 10 minutes 
before being stored at -20 ºC. 
 
2.5 Proteins 
 
(2.5.1) Purified His-tagged Interferon-α-2a (IFN α-2a) 
Purified His8-tagged IFN α-2a was supplied by Polytherics Ltd at a concentration of 0.5 
mg / ml in a buffer containing 20 mM Tris HCl, 100 mM NaCl and 10% glycerol. This protein 
was used in experiments as supplied.  
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2.6 Electrophoresis 
 
Electrophoresis is a common methodology used in molecular biology to separate small 
charged molecules. In this body of work, two electrophoresis methods have been employed; 
agarose gel electrophoresis to separate different length strands of Deoxyribose Nucleic Acid 
(DNA) and sodium dodecyl sulfate poly-acrylamide gel electrophoresis (SDS PAGE) to 
separate proteins of different molecular weights. Agarose gel electrophoresis was used to not 
only separate strands of DNA for isolation purposes, but also to identify whether genetic 
material from E.coli used to produce the target proteins was present in the different ATPS 
layers. SDS PAGE was used to determine successful production of the target protein 
conjugated to its fusion partner protein (e.g. glutathione s-transferase) as well as the location 
of proteins within the different ATPS layers. 
 
(2.6.1) Agarose Gel Electrophoresis 
Agarose gels were made by dissolving molecular biology grade agarose in 1 x TAE 
Buffer (2.2.1) and stained using ethidium bromide at a concentration of 0.5 µg / ml. The DNA 
and loading buffer (2.2.2) were then pipetted into the wells at the top of the gel and a current 
passed through at 10 V / cm until the dye front had travelled two-thirds of the gel length. The 
DNA could then be visualised by exposure to UV light and photographed using a UV 
transilluminator (UVP Products). 
 
(2.6.2) SDS Poly-Acrylamide Gel Electrophoresis (PAGE) 
To make a 10% resolving gel (5 ml), 1.25 ml of 40% acrylamide / bisacrylamide solution 
(Sigma-Aldrich) was combined with 1.25 ml of 50% glycerol, 1.25 ml of 4 x Tris pH 8.8, 1.15 
ml of distilled H2O, 50 µl of 10% SDS and 50 µl of 10% APS. This solution was mixed well with 
4.5 µl TEMED, overlaid with 0.5 ml 100% isopropanol and allowed to set within the sealed 
glass plates. A 5% stacking gel (2 ml) was made using 0.25 ml of 40% acrylamide / 
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bisacrylamide solution (Sigma-Aldrich) combined with 0.5 ml of 50% glycerol, 0.5 ml of 4 x 
Tris pH 6.5, 0.71 ml of distilled H2O, 20 µl of 10% SDS and 20 µl of 10% APS. This solution 
was mixed well with 2 µl TEMED and after removal of the 100% isopropanol, poured above 
the resolving gel up to approximately 2 cm below the rim of the lower glass plate. The comb 
was inserted into the gel which was allowed to set. When set, the gels are transferred into the 
gel tank containing 1 x running buffer (2.2.18). Samples to be run on the gel were heated at 
95°C for 5 minutes in 4 x sample buffer (2.2.19) and cooled to room temperature. Once loaded 
onto the gel with an appropriate molecular weight marker, the gel was run at 120 V until the 
dye front had moved into the resolving gel when the voltage was increased to 150 V. When 
ready the gels were carefully disassembled from the glass plates ready for coomassie staining 
or western blotting.   
 
2.7 Polymer Solutions 
 
 Careful consideration was taken when choosing polymers for this study. Not only was 
it important to ensure that two phases would be formed when the polymers were mixed in 
water, but biocompatibility had to be considered to allow for this protein purification method to 
be suitable for the production of therapeutic proteins. Poly(ethylene) glycol and dextran were 
both chosen due to their use as excipients in the pharmaceutical industry to provide long term 
stabilisation and bulking properties (Alpar, EK et al., 2004). Dextran is a polysaccharide made 
from many glucose monomers and is regularly used medically as a volume expander in 
hypovolaemia (Bulger, E., 2011). PEG and Dextran are both approved by the EU and FDA for 
use in both food (http://www.food.gov.uk/science/additives/enumberlist accessed 30/07/16) 
and medicines (Alconcel, S., et al., 2011) 
 
 
  
43 
 
(2.7.1) Poly(ethylene) Glycol 
Poly(ethylene) Glycol (PEG) of varying molecular weights was obtained from Sigma-
Aldrich and dissolved into double distilled water at the required concentration. PEG molecular 
weights used were as follows: 300 Da, 600 Da, 1000 Da, 1500 Da, 2000 Da, 4000 Da, 5000 
Da, 10000 Da and 20000 Da.  
 
(2.7.2) Dextran 
Dextran of varying molecular weights was obtained from Sigma-Aldrich and dissolved 
into double distilled water at the required concentration. Dextran molecular weights used were 
as follows: 6 kDa, 40 kDa, 70 kDa, 100 kDa, 200 kDa, 500 kDa and 2000 kDa.  
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2.8 General Techniques 
 
(2.8.1) Transformation of E.coli Tuner (DE3) Cells using CaCl2 Method 
A 30 ml starter culture was prepared by selecting a single E.coli Tuner colony from a 
fresh overnight streak plate and incubated overnight at 37°C in a shaking incubator. The cells 
were then harvested by centrifugation at 4000 rpm for 5 minutes after which the supernatant 
was discarded and any excess media drained away. The pellet was re-suspended in 6 ml of 
ice cold 50 mM CaCl2 (2.2.6) by gentle vortexing and then kept on ice for 10 minutes. 
Centrifugation was repeated and the pellet again re-suspended in 6 ml 50 mM CaCl2 and left 
to stand on ice for 10 minutes after which the centrifugation was repeated a third time. The 
pellet was then re-suspended in 1.2 ml of 50 mM CaCl2 and kept on ice for 20 minutes, during 
which time 1.5 ml microfuge tubes were chilled on ice in preparation for the transformation. 5 
ng of DNA to be transformed was prepared in 1.5 ml microfuge tubes on ice and 100 µl of 
E.coli Tuner cells were added. The tubes were mixed well and left on ice for 30 minutes, after 
which they were placed in a water bath at 37°C for 30 seconds to 1 minute and then returned 
to ice for a further 2 minutes. 0.5 ml LB Broth (2.1.1) was then added to the tubes which were 
then incubated in a 37°C water bath for 40 minutes. 100 µl and 200 µl aliquots of transformed 
cells were then plated out onto selective LB Agar (2.1.2) and incubated overnight at 37°C. 
 
(2.8.2) Expression of Protein in E.coli Tuner (DE3) Cells 
A single colony that had been freshly transformed with the desired plasmid DNA was 
selected and used to inoculate a 30 ml selective LB Broth starter culture (2.1.1) and was then 
incubated overnight in a 37°C shaking incubator. 5 ml of this overnight culture was then used 
to inoculate a 200 ml selective LB Broth and incubated at 37°C in a shaking incubator until an 
optical density of between 0.45 and 0.55 was achieved when analysed at a wavelength of 600 
nm. At this point 1 mM IPTG (2.2.12) was added, in order to induce the expression of the 
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desired protein, and the culture then incubated at 30°C in a shaking incubator until the desired 
amount of protein has been produced and the cells harvested by centrifugation. 
 
(2.8.3) His-Tag Purification of GFPuv 
His-tag purification of GFPuv was performed using Ni-NTA resin (QIAgen) and the 
protocol supplied by the manufacturer for purification from E.coli cell lysates under native 
conditions. 
 
(2.8.4) Initial formation of ATPS 
ATPS were formed by combining 0.5 ml of the required dextran solution and 0.5 ml of 
the required PEG solution in a 1.5 ml microfuge tube. The sample to be examined (100 µl) 
was then added at a known protein concentration (where relevant) and the system mixed by 
vortexing. The systems were then either left to settle for 30 minutes or centrifuged at 2000 g 
for 2 minutes at room temperature. Systems were then checked for a visible meniscus and 
those with a meniscus present were further analysed for protein and genomic material-
partitioning behaviours. 
 
(2.8.5) PEG M1a PEGylation of GSH 
PEGylation was performed by first combining 1.4 equivalent moles of GSH with 1 
equivalent mole of PEG M1a (Polytherics) in 3 ml of PEGylation reaction buffer as described 
in section (2.2.13) and left to react at room temperature for 18 hours and then freeze-dried 
overnight. Acetone precipitation of the PEGylated GSH was performed at -80°C on the residue 
to remove any un-reacted GSH. At each stage of acetone precipitation, filtration was also 
performed in order to remove any residual buffer salts. 1H NMR spectroscopy was performed 
on 10 mg of precipitate in D2O to determine the product obtained as described (2.8.17). 
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For 5 kDa PEGylated GSH  
 
1H NMR (400 MHz, D2O) δ 8.0 2H (d), 7.8 2H (d), 4.5 2H (d), 3.8 - 3.3 498H (methylene 
envelope), 3.25 3H (s), 3.1 1H (dd), 2.9 3H (m), 2.5 2H (m), 2.1 2H (m). 
 
For 10 kDa PEGylated GSH  
 
1H NMR (400 MHz, D2O) δ 8.0 2H (d), 7.8 2H (d), 4.5 2H (d), 3.8 - 3.3 640H (methylene 
envelope), 3.25 3H (s), 3.1 1H (dd), 2.9 3H (m), 2.5 2H (t), 2.1 2H (q). 
 
(2.8.6) Methoxy PEG Maleimide PEGylation of lysine NTA 
PEGylation was performed by first combining 5 equivalent moles of lysine NTA (Sigma, 
14580) with 1 equivalent mole of methoxy PEG maleimide (Jenkem USA Ltd.) in 5 ml of 
Sodium Phosphate buffer pH 6.0 (2.2.14) and left to react at room temperature for 24 hours. 
The conjugates were then separated from any unreacted lysine NTA and simultaneously 
exchanged into Sodium Acetate buffer pH 4.0 (2.2.16) using a PD10 desalting column (GE 
Healthcare) in preparation for copper coordination. Absorbance at A280 of each 1 ml elution 
from the PD10 column was measured using a quartz cuvette and the appropriate elutions 
were pooled. 1H NMR spectroscopy was performed on 10 mg of conjugate in D2O to determine 
the product obtained as described (2.8.17). 
 
For Lysine NTA  
 
1H NMR (400 MHz, D2O) δ 3.8 5H (m), 3.0 2H (t), 2.0 – 1.8 2H (m), 1.75 – 1.5 4H (m). 
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For 10 kDa Methoxy PEG Maleimide PEG  
 
1H NMR (400 MHz, D2O) δ 6.8 1H (s), 3.9 1H (m), 3.8 - 3.4 720H (methylene envelope), 3.3 
3H (s),  
 
(2.8.7) Conjugation of methoxy PEG amine to B1 Linker 
Prior to conjugation with the B1 linker, azeotropic drying of methoxy PEG amine was 
performed using 5 ml toluene under vacuum. Conjugation was then performed by combining 
4 equivalent moles of carboxylic DB-bis-sulfide linker (B1, obtained from Prof. Steve Brocchini, 
UCL) with 1 equivalent mole of Methoxy PEG amine (Jenkem USA Ltd.) in 5 ml Anhydrous 
Dichloromethane avoiding contact with air as much as possible. The flask was purged with 
Argon and, once sealed with parafilm, left to stir for 48 hours at room temperature. After the 
incubation period, the Anhydrous Dichloromethane was removed using rotary evaporation and 
the resulting precipitate dissolved into 5 ml acetone. This solution was filtered through cotton 
wool into a pre-weighed 50 ml falcon tube and placed onto dry ice for 5 minutes to precipitate 
the PEG conjugate. Centrifugation was performed at 4000 rpm for 30 minutes at -9°C and the 
supernatant discarded. The acetone precipitation and centrifugation steps were repeated 
twice more in order to remove any unreacted linker. After the final centrifugation step and the 
supernatant discarded, a needle was used to puncture the cap of the falcon tube and placed 
into a desiccator overnight. 1H NMR spectroscopy was performed on 10 mg of precipitate in 
D2O to determine the product obtained as described (2.8.17). 
 
For 10 kDa PEG B1 Sulfide  
 
1H NMR (400 MHz, D2O) δ 7.7 2H (d), 7.4 2H (d), 7.0 4H (s), 3.8 - 3.4 848H (methylene 
envelope), 3.3 3H (s), 3.1 1H (s), 2.2 3H (s), 1.3 – 1.1 3H (s). 
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(2.8.8) Oxidation of mPEG B1 
1 molar equivalent of mPEG B1 produced in method (2.8.7) was dissolved into 2.5 ml 
methanol in a round bottomed flask before the addition of 6 molar equivalents of Oxone 
(Sigma, 228036), 2.5 ml H2O, a magnetic stirrer and left overnight at room temperature. The 
insoluble Oxone was filtered away through cotton wool and the filtrate collected. The H2O and 
methanol was evaporated away using rotary evaporation and the residual precipitate 
dissolved into 5 ml acetone. This solution was filtered through cotton wool into a pre-weighed 
50 ml falcon tube and placed onto dry ice for 5 minutes to precipitate the PEG conjugate. 
Centrifugation was performed at 4000 rpm for 30 minutes at -9°C and the supernatant 
discarded. The acetone precipitation and centrifugation steps were repeated twice more in 
order to remove any unwanted compounds. After the final centrifugation step and the 
supernatant discarded, a needle was used to puncture the cap of the falcon tube and placed 
into a desiccator overnight. 1H NMR spectroscopy was performed on 10 mg of precipitate in 
D2O to determine the product obtained as described (2.8.17). 
 
For 10 kDa PEG B1 Sulfone 
 
1H NMR (400 MHz, D2O) δ 7.7 2H (d), 7.5 2H (d), 7.4 4H (m), 3.9 - 3.5 583H (methylene 
envelope), 3.45 3H (s), 2.4 2H (s). 
 
(2.8.9) Conjugation of mPEG B1 Sulfone to lysine NTA 
PEGylation was performed by first combining 5 equivalent moles of lysine NTA (Sigma, 
14580) with 1 equivalent mole of mPEG B1 Sulfone (2.8.8) in 5 ml of Tris buffer pH 9.0 (2.2.17) 
and left to react at 37°C overnight. The conjugates were then separated from any unreacted 
lysine NTA and simultaneously exchanged into Sodium Acetate buffer pH 4.0 (2.2.16) using 
a PD10 desalting column (GE Healthcare) in preparation for copper coordination. Absorbance 
at A280 of each 1 ml elution from the PD10 column was measured using a quartz cuvette and 
49 
 
the appropriate elutions pooled. 1H NMR spectroscopy was performed on 10 mg of conjugate 
in D2O to determine the product obtained as described (2.8.17). 
 
For 10 kDa PEG B1 lysine NTA 
 
1H NMR (400 MHz, D2O) δ 7.5 2H (d), 7.35 2H (d), 3.9 - 3.4 1264H (methylene envelope), 3.3 
3H (s), 3.0 4H (m), 2.0 – 1.75 4H (m), 1.75 – 1.35 8H (m). 
 
(2.8.10) Conjugation of amine PEG amine to B1 Linker 
Prior to conjugation with the B1 linker, azeotropic drying of amine PEG amine was 
performed using 5 ml toluene under vacuum. Conjugation was then performed by combining 
8 equivalent moles of carboxylic DB-bis-sulfide linker (B1, obtained from Prof. Steve Brocchini, 
UCL) with 1 equivalent mole of amine PEG amine (Jenkem USA Ltd.) in 5 ml Anhydrous 
Dichloromethane avoiding contact with air as much as possible. The flask was purged with 
Argon and, once sealed with parafilm, left to stir for 48 hours at room temperature. After the 
incubation period, the Anhydrous Dichloromethane was removed using rotary evaporation and 
the resulting precipitate dissolved into 5 ml acetone. This solution was filtered through cotton 
wool into a pre-weighed 50 ml falcon tube and placed onto dry ice for 5 minutes to precipitate 
the PEG conjugate. Centrifugation was performed at 4000 rpm for 30 minutes at -9°C and the 
supernatant discarded. The acetone precipitation and centrifugation steps were repeated 
twice more in order to remove any unreacted linker. After the final centrifugation step and the 
supernatant discarded, a needle was used to puncture the cap of the falcon tube and placed 
into a desiccator overnight. 1H NMR spectroscopy was performed on 10 mg of precipitate in 
D2O to determine the product obtained as described (2.8.17). 
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(2.8.11) Oxidation of PEG Bis-B1 
1 molar equivalent of PEG Bis-B1 produced in method (2.8.10) was dissolved into 2.5 
ml methanol in a round bottomed flask before the addition of 12 molar equivalents of Oxone 
(Sigma, 228036), 2.5 ml H2O, a magnetic stirrer and left overnight at room temperature. The 
insoluble Oxone was filtered away through cotton wool and the filtrate collected. The H2O and 
methanol was evaporated away using rotary evaporation and the residual precipitate 
dissolved into 5ml acetone. This solution was filtered through cotton wool into a pre-weighed 
50 ml falcon tube and placed onto dry ice for 5 minutes to precipitate the PEG conjugate. 
Centrifugation was performed at 4000 rpm for 30 minutes at -9°C and the supernatant 
discarded. The acetone precipitation and centrifugation steps were repeated twice more in 
order to remove any unwanted compounds. After the final centrifugation step and the 
supernatant discarded, a needle was used to puncture the cap of the falcon tube and placed 
into a desiccator overnight. 1H NMR spectroscopy was performed on 10 mg of precipitate in 
D2O to determine the product obtained as described (2.8.17). 
 
(2.8.12) Conjugation of PEG Bis-B1 Sulfone to lysine NTA 
PEGylation was performed by first combining 10 equivalent moles of lysine NTA 
(Sigma, 14580) with 1 equivalent mole of mPEG bis-B1 Sulfone (2.8.11) in 5 ml of Tris buffer 
pH 9.0 (2.2.17) and left to react at 37°C overnight. The conjugates were then separated from 
any unreacted lysine NTA and simultaneously exchanged into Sodium Acetate buffer pH 4.0 
(2.2.16) using a PD10 desalting column (GE Healthcare) in preparation for copper 
coordination. Absorbance at A280 of each 1 ml elution from the PD10 column was measured 
using a quartz cuvette and the appropriate elutions pooled. 1H NMR spectroscopy was 
performed on 10 mg of conjugate in D2O to determine the product obtained as described 
(2.8.17). 
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(2.8.13) Coordination of Copper Ions to PEGylated lysine NTA compounds 
 Copper Sulfate (CuSO4) was added to pooled fractions of the PEGylated NTA 
compounds that were buffer exchanged into Sodium Acetate buffer pH 4.0 (2.2.16). Differing 
molar equivalents were added to the different PEGylated lysine NTA compounds available (5 
molar equivalents of CuSO4 for mPEG Maleimide, 10 molar equivalents of CuSO4 for mPEG 
B1 and 20 molar equivalents of CuSO4 for PEG bis-B1 lysine NTA). The coordination reactions 
were left at room temperature overnight and buffer exchanged into ATPS phosphate buffer 
pH 8.0 (2.2.15) in preparation for use in ATPS. 
 
(2.8.14) Bradford assay Standard Method 
Bradford reagent (Bio-Rad Laboratories Inc.) was diluted 1 part dye to 4 parts distilled 
H2O and filtered through filter paper. Bovine Serum Albumin (BSA) standards were produced 
in triplicate with concentrations ranging between 0.05 mg / ml to 0.5 mg / ml. 10 µl of the 
sample to be analysed was mixed with 200 µl of diluted Bradford reagent, comprising 
coomassie brilliant blue dye, phosphoric acid and methanol, followed by a 5 minute incubation 
at room temperature. A spectrophotometer was used to read the absorbance of the samples 
at a wavelength of 595 nm as described by Bradford, M.M., 1976.  
 
(2.8.15) Bradford assay Microplate Method 
Bradford reagent (Bio-Rad Laboratories Inc.) was diluted 1 part dye to 4 parts distilled 
H2O and filtered through filter paper. Bovine Serum Albumin (BSA) standards were produced 
in triplicate with concentrations ranging between 8 µg / ml to 80 µg / ml. 160 µl of the sample 
to be analysed was mixed with 40 µl of diluted Bradford, comprising coomassie brilliant blue 
dye, phosphoric acid and methanol, followed by a 5 minute incubation at room temperature. 
A spectrophotometer was used to read the absorbance of the samples at a wavelength of 595 
nm as described by Bradford, M.M., 1976. 
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(2.8.16) ATPS Formation with Affinity Conjugates 
ATPS (1.5 g systems) were formed by weighing out the required molecular weight 
dextran and molecular weight PEG polymers into a 1.5 ml microfuge tube. To this was added 
the appropriate volume of known concentration functionalised PEG and 100 µl of the sample 
to be examined. Finally ATPS phosphate buffer (2.2.15) was added to produce a final system 
weight of 1.5 g. The systems were mixed by vortexing and were then left to settle for 30 
minutes at room temperature. Systems were then checked for a visible meniscus and those 
with a meniscus present were further analysed for protein partitioning behaviours. 
 
(2.8.17) 1H NMR Spectroscopy 
 1H NMR spectroscopy was carried out using a Bruker 400 spectrometer. Chemical 
shifts are measured in ppm, and multiplicity denoted as follows: s = singlet, d = doublet, dd = 
double doublet, t = triplet, q = quartet, m = multiplet.  
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2.9 Enzyme Techniques 
 
(2.9.1) SmaI, Antarctic Phosphatase and EcoRI Digestion Protocol 
One unit of SmaI was used to digest 1 µg DNA in 1 hour at 25 ºC in a total reaction volume 
of 50 µl. This was followed by Antarctic Phosphatase and then subsequent heat inactivation 
at for 20 mins at 65 ºC. The product was purified directly from the enzyme buffer mixture using 
a GeneClean purification kit which utilises GLASSMILK® nucleic acid binding matrix. The 
purified product was subsequently digested using one unit of EcoRI (New England BioLabs 
Inc.) to digest 1 µg DNA in 1 hour at 25 ºC in a total reaction volume of 50 µl, followed by heat 
inactivation at 65 ºC for 20 mins.  
 
(2.9.2) BamHI Digestion Protocol 
BamHI (New England BioLabs Inc.) was used at 1/10th of the concentration recommended 
by the manufacturers and for only a 10 minute incubation period at 37 ºC to produce 
incomplete digestion. As heat inactivation is not effective on BamHI, the product was quickly 
purified using directly from the enzyme buffer mixture using a GeneClean purification kit which 
utilises GLASSMILK® nucleic acid binding matrix. 
  
(2.9.3) BamHI, Mung Bean Nuclease and EcoRI Digestion Protocol 
One unit of BamHI (New England BioLabs Inc.) was used initially for one hour at 37 ºC in 
a total reaction volume of 50 µl, followed by the addition of 4.5 units of Mung Bean Nuclease 
(New England BioLabs Inc.) and incubated at 30°C for 30 minutes. After purification of the 
product using a GeneClean purification kit, one unit of EcoRI (New England BioLabs Inc.) was 
used to digest the product in a total reaction volume of 50 µl at 37 ºC, followed by heat 
inactivation for 20 mins at 65 ºC.  
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(2.9.4) T4 DNA Ligase Ligation Protocol 
One unit of T4 DNA Ligase (New England BioLabs Inc.) was used with the supplied buffer. 
Reactions were left overnight at 16°C in a total reaction volume of 20 µl. 
 
(2.9.5) Polymerase Chain Reaction (PCR) Protocol 
PCR was performed using Pfu Polymerase (New England BioLabs Inc.) or Taq 
Polymerase (New England BioLabs Inc.) at 75 ºC in 1 x standard reaction buffer.  Primers 
used in this instance are described in section 2.4.
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Chapter 3. Behaviour of E.coli cell lysates in poly(ethylene 
glycol) (PEG) and dextran (DEX) aqueous two phase systems 
(ATPS) 
 
3.1 Introduction 
 
 ATPS can be formed using varying concentrations of polymer solutions that are 
sufficiently disparate to produce a difference in water concentration around the polymer 
chains (Albertsson, 1986.). In this work poly(ethylene glycol) (PEG) and dextran (DEX) 
systems were systematically analysed to find the optimal concentrations and molecular 
weights of these two polymers to first form an interface and then two distinct phases to 
give an ATPS. Secondly, cell lysate was added to the resulting ATPS. The PEG phase 
was the upper or top phase, and DEX phase was the lower phase of the ATPS. 
Optimisation of the ATPS was conducted in an effort to partition the cell lysate 
components to the lower DEX phase. Protein detection was performed using the 
Bradford assay and visually determined using the location of fluorescence from green 
fluorescent protein (GFPuv) contained within the cell lysate. The location within the 
ATPS of cellular DNA and RNA was analysed using ethidium bromide staining of 
agarose gels obtained after electrophoresis.   
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3.2 Formation of ATPS 
 
To determine which combinations of PEG and Dextran would form an ATPS, a 
range of molecular weight PEG and DEX, in 10% (w/v), 20% (w/v) and 25% (w/v) 
concentrations were combined as described in section (2.8.4). These systems (Tables 
3.1 A-C) were allowed to settle for 30 minutes at room temperature.  
 
As can be seen from Table 3.1 A-C, there was a similar trend in all cases, where 
combinations of higher molecular weight PEG and DEX solutions successfully formed 
ATPS (there was a visible meniscus), whilst polymer mixtures of lower MW did not, 
Table 3.1: Formation of ATPS using various concentrations of PEG and dextran solutions.  
ATPS were formed by settling, as described (2.8.4). All Experiments were performed in triplicate. 
Grey shading indicates the successful formation of two phases. A, 10% (w/v) polymer solutions; 
B, 20% (v) polymer solutions; C, 25% (w/v) polymer solutions. 
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although it is noticeable that higher concentrations of polymer prompted successful 
ATPS formation with the polymer solutions of lower MW. However, the 25% (w/v) 
polymer solutions had sufficiently high viscosity to make accurate pipetting problematic. 
Since 10% (w/v) polymer solutions gave fewer options for ATPS formation, 20% (w/v) 
polymer solutions were chosen for use in future studies.  
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3.3 Protein assays in the presence of PEG and/or Dextran polymer 
solutions 
 
Prior to analysing partitioning behaviour in 20% ATPS, it was necessary to 
determine whether the Bradford assay would function in the presence of ATPS 
components and/or be affected by those components. Accordingly, Bovine Serum 
Albumin (BSA) standard solutions were measured by the Bradford assay (2.8.14) in the 
presence or absence of 10 µl of 20% DEX 100 and 20% PEG 2000 (an 80 fold dilution). 
 
 
Figure 3.1: Comparison of Bradford assay performance in the presence / absence ATPS 
components. BSA stock solutions were quantified as described (2.8.1) with or without 0.25% 
(w/v) PEG 2000 or 0.25% (w/v) DEX 100, where 0.25% represents an 80-fold dilution of the 
standard ATPS component concentration. 
 
 
Figure 3.1 confirms the earlier finding of Barbosa et al (2009) that these ATPS 
reagents have only a very minor influence on Bradford assay results at the diluted 
concentrations required for the assay. Further analysis of each of the individual polymer 
solutions used in making the various ATPS combinations showed a similarly low 
absorbance in the presence of Bradford reagent (Table 3.2).  
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Polymer	 Optical	Density	(595nm)	
PEG	1500	 0.016	
PEG	2000	 0.022	
PEG	4000	 0.018	
PEG	20000	 0.020	
Dextran	40	 0.009	
Dextran	70	 0.012	
Dextran	100	 0.010	
Dextran	200	 0.012	
Dextran	500	 0.007	
Dextran	2000	 0.009	
 
Table 3.2: Optical densities obtained by Bradford analysis of various 80-fold diluted 
polymer solutions (0.25%, w/v). Bradford analyses of each diluted solution were performed as 
described (2.8.14). 
 
3.4 ATPS performance in the presence of cell lysates: settling versus 
centrifugation 
 
Many examples are described in the literature of ATPS formed by either 
centrifugation and or by settling, however studies comparing the two methods are not 
available. To determine which method is superior for the PEG-DEX system, it was 
necessary to investigate the difference in the partitioning behaviour between systems 
that were left to settle and systems that were centrifuged. Since the ultimate aim of this 
study is to purify proteins directly from cell lysates, ATPS performance was initially 
assessed using cleared E. coli cell lysates. To facilitate evaluation, lysates containing 
expressed GFPuv were studied. 
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3.4.1 Comparison of ATPS formation from 20% polymer solutions in the 
presence of cell lysate, either by settling or centrifugation. 
 
It had previously been demonstrated that 20% solutions of PEG and DEX form 
an ATPS using various combinations of high MW polymers (Table 3.1 B). ATPS 
formation might be affected by the presence of E. coli lysate and/or by the experimental 
protocol adopted. The ATPS formation experiment (section 3.2) with 20% (w/v) polymer 
solutions was therefore repeated in the presence of 100 µl E. coli lysate containing 
GFPuv, by both settling and centrifugation methodologies (Table 3.3). 
 
 
 
Table 3.3: Comparison of methodologies for formation of ATPS containing E. coli cell 
lysate. ATPS were formed either by settling (A) or by centrifugation (B). Each ATPS contained 
cleared E.coli Cell lysate (100µl) containing expressed GFPuv. Total protein concentration within 
the lysate was 730 µg/ml, as determined by the Bradford method (2.8.14). Green colouration 
indicates successful ATPS formation. 
 
 
It is interesting to note that addition of cell lysate to the ATPS reduced the overall 
number of polymer combinations that formed an ATPS (Table 3.1B and Table 3.3 A-B).  
Specifically, combinations with the lower molecular weight polymers failed to form ATPS 
in the presence of cell lysate.  However, results shown in Table 3.3 suggest that there is 
little difference between the two methodologies in terms of the successful formation of 
an ATPS. In fact, by comparing Tables 3.3 A and B, it can be seen that only one 
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additional ATPS, namely PEG 2000 and DEX 200 was formed when settling rather than 
centrifugation methodology was employed. 
 
3.4.2 Comparison of ATPS partitioning performance from 20% polymer 
solutions in the presence of cell lysate, either by settling or centrifugation. 
 
Those systems which had successfully formed ATPS in section 3.4.1 were 
further analysed to examine partitioning performance in terms of both protein and nucleic 
acid separation. Simple observation of such systems demonstrated that all visually-
detectable GFPuv had partitioned to the lower, DEX layer in all cases. However, GFPuv 
partitioning behaviour is not necessarily indicative of total cell protein behaviour. 
Therefore, both the top (PEG) and bottom (DEX) layers of the formed ATPS, shown in 
green in Table 3.3, were analysed for total protein concentration using the Bradford 
assay (2.8.14; Figure 3.2). 
A standard curve for the Bradford assay was produced to allow for the 
determination of protein concentration when an optical density reading was obtained for 
a sample (Figure 3.2).  
 
 
Figure 3.2: Bradford assay standard curve for settled (A) and centrifuged (B) systems. The 
standard was produced using known concentrations of BSA prepared from stock solution as 
described in section (2.2.8) of “Materials and Methods” 
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The optical densities recorded for each phase were analysed using the equations 
obtained from the Bradford assay standard curves shown above in Figure 3.2. An 
additional value for polymer interference, as determined from Table 3.2, was subtracted 
from the appropriate optical density so that the percentage of protein partitioning in that 
layer could be estimated (Figure 3.3). 
 
 
In Figure 3.3 above it can be seen that there is near complete protein partitioning 
to the lower DEX phase with only two systems (Figure 3.3 A), namely PEG 20000 / DEX 
70 and PEG 20000 / DEX 2000 having proteins present in the upper PEG phase when 
formed using the settling methodology. This indicates that there is little difference 
between the two methodologies of settling and centrifugation when partitioning proteins 
within a cell lysate. 
 
Figure 3.3: Phase partitioning of cellular protein to upper PEG (A) and lower DEX (B) 
phases when utilising the settling methodology. The phase partitioning to upper PEG (C) and 
lower DEX (D) phases of centrifuged systems are also shown (2000g for 2 minutes). 
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To further analyse the molecular partitioning characteristics of these PEG-DEX 
systems, DNA partitioning analysis was performed using agarose gel electrophoresis 
(2.6.1). ATPS that were formed using cell lysate (Figure 3.4) were used in these 
experiments. 
 
 
 
 
There was no genomic material present in the top PEG layers of any of the ATPS 
(Figure 3.4), indicating complete DNA partitioning to the lower DEX layer when either 
settling or centrifugation methodologies are employed.  
Figure 3.4: Agarose electrophoresis gels showing the partitioning of genomic DNA in ATPS 
formed by settling (A) and centrifugation (B). 10µl of each ATPS layer was electrophoresed on a 
1% agarose gel that was pre-stained with ethidium bromide as described in section (2.6.1) of “Materials 
and Methods”. Lanes A1: PEG 2000 / DEX 200 ATPS, A2: PEG 2000 / DEX 500 ATPS, A3: PEG 2000 
/ DEX 2000 ATPS, A4: PEG 4000 / DEX 40 ATPS, A5: PEG 4000 / DEX 70 ATPS, A6: PEG 4000 / 
DEX 100 ATPS, A7: PEG 4000 / DEX 200 ATPS, A8: PEG 4000 / DEX 500 ATPS, A9: PEG 4000 / 
DEX 2000 ATPS, A10: PEG 20000 / DEX 40 ATPS, A11: PEG 20000 / DEX 70 ATPS, A12: PEG 
20000 / DEX 100 ATPS, A13: PEG 20000 / DEX 200 ATPS, A14: PEG 20000 / DEX 500 ATPS, A15: 
PEG 20000 / DEX 2000 ATPS and A16: original cell lysate (no ATPS). B1: original cell lysate (no 
ATPS); B2:  PEG 2000 / DEX 500 ATPS; B3: PEG 2000 / DEX 2000 ATPS; B4: PEG 4000 / DEX 40 
ATPS; B5: PEG 4000 / DEX 70 ATPS; B6: PEG 4000 / DEX 100 ATPS; B7: PEG 4000 / DEX 200 
ATPS; B8: PEG 4000 / DEX 500 ATPS; B9: PEG 4000 / DEX 2000 ATPS; B10: PEG 20000 / DEX 40 
ATPS; B11: PEG 20000 / DEX 70 ATPS; B12: PEG 20000 / DEX 100 ATPS; B13: PEG 20000 / DEX 
200 ATPS; B14: PEG 20000 / DEX 500; ATPS and B15: PEG 20000 / DEX 2000 ATPS where in each 
case the upper half on the lane represents contents of the upper, PEG phase and the lower half of the 
lane represents the contents of the lower, DEX phase. 
 A  1    2    3    4    5     6    7    8    9   10  11  12  13  14  15   16     B     1    2    3   4    5    6    7    8    9  10  11   12  13  14  15 
PEG phase 
DEX phase 
DEX phase 
DEX phase 
PEG phase 
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3.5 Purified GFPuv Partitioning Analysis in Settled and Centrifuged ATPS 
 
To determine whether other components of the lysate would influence the partitioning 
behaviour of the GFPuv protein, the experiments in section 3.2 were repeated using GFPuv 
that had been purified by his-tag purification.  
 
 
 
 
Figure 3.5: Phase partitioning of 100µl purified GFPuv to upper PEG (A) and lower DEX (B) 
phases when utilising the settling methodology. The phase partitioning to upper PEG (C) and lower 
DEX (D) phases of centrifuged systems are also shown (2000g for 2 minutes). 
 
It can be seen above (Figure 3.5 A and B) that there is a clear trend in settled ATPS 
in which the majority of protein partitioned to the lower DEX phase when higher molecular 
weight polymers are employed. Whereas the lower molecular weight polymers, showed more 
even partitioning of purified GFPuv between the two layers. This trend is exemplified most 
strongly by the PEG 1500 Da and DEX 2000 kDa system in which partitioning is approaching 
a 50 / 50 distribution. In contrast, when using the centrifugation method to partition purified 
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GFPuv, there is no clear trend in partitioning behaviour therefore making the use of centrifuged 
systems less predictable. As there was no genomic material present in the purified GFPuv, 
DNA partitioning analysis was not performed. 
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3.6 Conclusion 
 
 The work in this chapter has laid the foundations for the proceeding chapters 
experiments by determining the experimental parameters to be employed. As the physical 
properties of the polymer solutions with differing molecular weights and concentrations were 
unknown, these initial experiments were essential to assess their suitability. Due to there not 
being a general consensus in current literature with regards to a generic ATPS composition, 
this work is the basis for a step towards a simple, generic system that could be prepared easily 
and quickly in both a research and industrial setting.  
In this case, the results (Table 3.1) obtained from section 3.2 indicated that 25% (w/v) 
polymers had reduced accuracy due to high viscosity and 10% (w/v) polymers did not produce 
a wide enough variety of ATPS for analysis. Due to this, 20% (w/v) polymer solutions were 
determined to be suitable polymer concentrations and therefore chosen for further studies. 
Prior to the secondary study in this chapter starting, the effect of PEG or dextran on protein 
assays was investigated to ensure that the Bradford assay accuracy wasn’t impeded. The 
results shown in figure 3.1 demonstrate that the polymers are diluted sufficiently to not 
interfere with protein detection during the Bradford assay, as supported by Barbosa et al, 
2009. This finding was further supported in Table 3.2 where all polymers showed very low 
readings when analysed using Bradford reagent in the absence of protein. These results 
demonstrate that samples can be analysed for protein concentration directly from the ATPS, 
without the need for an additional purification step. These results demonstrate that this 
separation method can be easily analysed and therefore has potential for development into a 
commercial methodology. 
 The secondary study in this chapter systematically analysed the effect of cell lysate 
addition to the previously investigated 20% (w/v) combinations of polymers on the formation 
of two distinct phases. Upon the addition of cell lysates to ATPS formed using 20% (w/v) 
polymer solutions of varying molecular weights, it was determined that polymer combinations 
67 
 
of PEG and DEX, both of higher molecular weights, were more effective at partitioning of 
cellular proteins, GFPuv (Figure 3.3) and genomic DNA (Figure 3.4) to the DEX phase of the 
ATPS. These results (Table 3.3) also showed that allowing the systems to settle, instead of 
employing the centrifugation methodology, produced greater ATPS variants with complete 
lower phase partitioning. This was ideal for following experiments due to an affinity method 
being used to separate GFPuv into the upper PEG phase from the remaining cellular 
components in the lower DEX phase.  
 The behaviour of purified GFPuv in ATPS was also analysed to determine the effect 
of cellular components, within cell lysates, on GFPuv partitioning. The results shown in figure 
3.5 demonstrate that his-tag purified GFPuv does not exhibit purely lower DEX phase 
partitioning but was also spread into the upper PEG phase. This indicates that other cellular 
components present in cell lysate do have a partitioning effect on GFPuv. This effect could 
potentially be overcome using PEGylated affinity ligands, developed in subsequent chapters, 
to ensure upper PEG phase partitioning of the desired protein. This lower DEX phase 
partitioning effect of cell lysate debris was desirable for the further development of affinity 
ATPS into a generic system as all detectable levels of undesired contaminants were 
partitioned away from the upper PEG phase.  
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Chapter 4. Affinity ATPS using reduced glutathione and 
glutathione S-transferase fused proteins. 
 
4.1 Introduction 
 
 The aim of this work was to use PEGylated, reduced glutathione (GSH) as an 
affinity ligand in ATPS. Studies of ATPS combinations featuring differing concentrations 
and molecular weights of PEG and DEX have shown that complete partitioning of all 
cellular components into the dextran layer preferentially occurs at both higher molecular 
weights and concentrations of the polymers (Chapter 3). It was also determined that the 
settling methodology was preferable for ATPS formation due to complete protein, cell 
debris and genomic material partitioning to the lower DEX phase (Chapter 3.4.2). Thus 
the hypothesis behind work in this chapter was that the PEGylation of GSH could help 
to partition glutathione S-transferase (GST) fused proteins into the upper PEG layer of 
the ATPS. (Figure 4.1).  
 
 
 
 
Figure 4.1: Schematic of an ATPS system comprising a lower DEX phase and upper PEG 
phase. Cell lysate containing the GST-GFPuv fusion protein was added to the system along with 
PEGylated GSH. 
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The PEGylated ligand should remove the fusion protein of interest into the upper 
phase, and therefore away from any cellular debris and native proteins. To facilitate 
visualisation, green fluorescent protein (GFPuv) was expressed as a glutathione S-
transferase fusion (GST-GFPuv) for use in these studies. The expression of GST-GFPuv 
(Chapter 4.2), the synthesis of PEGylated reduced glutathione (PEG-GSH) (Chapter 4.4) 
and their evaluation in ATPS partitioning (Chapter 4.6) are described.  
 
4.2 Expression of GST-GFPuv fusion protein 
 
 The GFPuv gene was amplified from the pGFPuv vector (Clontech) using the 
primers presented in methods 2.4.1 and 2.4.2. Due to presence of a BamHI site within 
the required GFPuv gene (shown in appendix 4.1) it was not possible to simply perform 
a straightforward restriction digest and ligation. To circumnavigate this (cloning 
schematic demonstrated in Figure 4.2), the GFPuv gene was amplified from the pGFPuv 
plasmid with modified primers to insert a SmaI restriction enzyme site at the 5’ end of 
the gene and a 3’ EcoRI site. SmaI was employed first to cut the GFPuv insert at the 5’ 
end, followed by EcoRI to digest the 3’ end of the gene (Methods 2.9.1). The plasmid 
pGEX2TK was prepared by first digesting with BamHI (Methods 2.9.2) resulting in a 
linearised vector with 5’ overhangs. Mung bean nuclease was used to remove these 5’ 
overhangs, followed by EcoRI digestion (Methods 2.9.3). The resulting pGFPuv insert 
was ligated into the pGEX2TK vector using T4 DNA ligase (Methods 2.9.4). The resulting 
construct was sent for sequencing to the Birmingham University Functional Genomics 
Laboratory which confirmed the sequence structure (Appendix 4.1 plasmid map + 
sequence of fusion). 
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Figure 4.2: Schematic demonstrating the cloning of the GFPuv gene into the pGEX2TK 
vector. 
 
E. coli Tuner (DE3) bacterial cells were prepared and transformed with the 
resulting vector containing the GST-GFPuv fusion gene (Methods 2.8.1). Expression of 
the GST-GFPuv gene was performed in E. coli Tuner DE3 cells induced with 1 mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG). Preliminary expression at 37°C gave 
poor yields of soluble protein, but good yields were obtained successfully at a 30°C 
growth temperature (Methods 2.8.2). A fraction of the resulting culture (50 ml) was 
harvested by centrifugation and lysed using the commercial reagent Bugbuster™, with 
the remainder of the culture (150 ml) frozen at -20°C for future use. The desired GST-
GFPuv fusion protein was purified by affinity chromatography (Methods 2.8.3) followed 
by analysis using polyacrylamide agarose gel electrophoresis (PAGE; Methods 2.6.2; 
Figure 4.3).  
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Elutions 2-5 (250 µl each; Figure 4.3) were pooled to generate the purified GST-
GFPuv fusion protein for use in future experiments and quantified by the Bradford assay 
(Method 2.8.14), yielding a total volume of 1 ml GST-GFPuv fusion protein at a final 
concentration of 4.09 mg/ml. 
 
4.3 Partitioning of purified GST-GFPuv   
 
In Chapter 3, it was established that many combinations of higher molecular 
weight PEG and DEX ATPS, when using the settling methodology, partitioned both total 
E. coli nucleic acid and proteins into the lower DEX layer. To ensure that this finding was 
consistent with the behaviour of purified GST-GFPuv, the partitioning of this fusion 
protein was examined with a range of ATPS conditions.  
 
    1       2      3      4      5       6      7     8      9      M 
GST-GFPuv Fusion Protein 
Figure 4.3: Polyacrylamide gel electrophoresis of GST-GFPuv purification. 12% PAGE gel, 
stained with Coomassie Blue.  Lanes: 1) Column flow through; 2-4) Washes 1-3; 5-9) Elutions 1-
5; M) 15 µl NEB ColorPlus™ Prestained Protein Marker, Broad Range (7-175 kDa). All other 
samples were 5 µl of original material. 
 
GFPuv-GST 
GST 
GFPuv 
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As Figure 4.4 shows, GST-GFPuv partitioned predominantly into the lower DEX 
phase when the higher molecular weight PEGs (20000 Da and 4000 Da) were used. In 
contrast, when PEG 2000 Da was used, protein had partitioned into the upper PEG 
phase indicating that higher molecular weight PEGs are desirable. This is supported in 
the literature with Johansson et al., (2008) describing a decrease in the partitioning 
coefficient (K) of GFPuv with an increase of PEG molecular weight. For the purposes of 
this study, a low K for GFPuv and other cellular components is desirable as the 
PEGylated affinity ligand should overcome this, allowing for upper PEG phase 
partitioning of only the required GST-GFPuv fusion protein. 
 
 
 
 
 
 
PEG 4000 
 PEG 20000 
 
PEG 2000 
 PEG 4000 
 
PEG 2000 
 
PEG 20000 
 
A B 
Figure 4.4: Histograms demonstrating the distribution of purified GST-GFPuv fusion 
across PEG and DEX layers of ATPS of various compositions. Solutions of polymers (0.5 ml, 
20% (w/v) PEG 20000 Da, 4000 Da, 2000 Da and DEX 2000 kDa, 500 kDa, 200 kDa, 100 kDa, 
70 kDa and 40 kDa) were combined as indicated to form ATPS with 100 µl purified GST-GFPuv 
fusion protein (4.09 mg/ml). Protein concentration was determined by the Bradford assay. Note 
that PEG 2000 Da and DEX 40 kDa failed to form two distinct phases. 
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4.4 Synthesis of PEGylated GSH Ligands 
 
 PEGylation of GSH was performed using the M1a PEGylation reagent (Methods 
2.8.5; Scheme 4.1, 1; provided by Polytherics Ltd.) which links one PEG molecule to the 
thiol of a single GSH molecule (2). The conjugates were made in both 5 kDa and 10 kDa 
forms of PEG and then the conjugate was purified (Methods 2.8.5). The reaction for the 
conjugation of M1a PEG-GSH (3) is illustrated in Scheme 4.1.  
 
 
 
 
Scheme 4.1: Conjugation of PEG M1a to reduced glutathione. i – PEGylation reaction buffer 
(2.2.11); 18 hours; room temperature. 
 
The resulting conjugates were examined by 1H NMR spectroscopy (Figure 4.5 A 
and B; interpretation in Methods 2.8.5) and then stored at -20°C under argon, until 
required. 1H NMR spectroscopy was selected for this analysis as it was possible to 
confirm the structure of the analyte ensuring its suitability for further experimentation. 
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Figure 4.5: 1H NMR Spectrum of 5 kDa PEGylated GSH 
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Figure 4.6: 1H NMR Spectrum of 10 kDa PEGylated GSH  
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4.5 Investigation of interactions between PEGylated GSH ligands and GST fused 
protein 
  
As commercially reduced GSH can be immobilised onto solid support using the thiol 
group, via a linker (Figure 4.7), it is suggested that the site specific PEGylation of the thiol 
within GSH should not interfere with its subsequent binding with GST. It is therefore a 
reasonable assumption, that a free thiol on GSH is not required for binding to GST.  
 
 
Figure 4.7: Chemical structure demonstrating the binding of glutathione to an agarose solid 
support via a 12 atom spacer in the commercially available Thermo Scientific Pierce Glutathione 
Agarose. (Image reproduced from http://www.piercenet.com/product/pierce-glutathione-agarose-kits) 
  
However, the steric shielding caused by the 5- or 10- kDa PEG (relative to GSH, which 
has a MW of 307 Da) might also prevent an effective interaction between PEGylated GSH and 
GST. To examine this possibility, the ability of both 5- and 10- kDa PEGylated GSH to elute 
GST-GFPuv fusion protein from glutathione sepharose was investigated. A fresh preparation 
of cleared, concentrated E. coli lysate containing the GST-GFPuv fusion protein was prepared 
and 0.5 ml concentrated cell lysate (2.8.2) was applied separately to two 0.25 ml bed volume 
glutathione sepharose columns (GE Healthcare). Initially, to confirm appropriate test 
conditions, these columns were then eluted with either 10 mM glutathione in 50 mM Tris-HCl 
pH 8.0 (as per manufacturer’s instructions), or by 50 mM Tris-HCl pH 8.0 alone. Interestingly, 
both conditions caused the fusion protein to elute from the column, with elution being complete 
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by the end of the third application of 0.25 ml elution buffer. A further control experiment was 
then performed in which elution with water was attempted. Here, elution was limited to minimal 
leaching, whilst the vast majority of the fusion protein remained bound to the column. Water 
was tested for elution since it was planned that subsequent ATPS experiments would be 
performed in water. 
 As previously, 0.5 ml cleared, concentrated E. coli lysate containing GST-GFPuv 
fusion protein was applied to two 0.25 ml bed volume glutathione sepharose columns. Each 
column was eluted with either 4 × 0.25 ml 1 mM 5 kDa PEG-GSH or 4 × 0.25 ml 1 mM 10 kDa 
PEG-GSH, both in water. Eluted fractions were then examined for GFPUV fluorescence. As 
previously, elution of the fusion protein was complete by the end of the third application of 
0.25 ml elution buffer. Since water alone failed to elute the fusion protein, it was concluded 
that both 5 kDa PEG-GSH and 10 kDa PEG-GSH were capable of binding to the GST element 
of the GST-GFPuv fusion protein. Both PEG-GSH conjugations were therefore deemed 
suitable for further experimentation within ATPS to determine their efficacy at partitioning the 
GST-GFPuv fusion protein into the upper PEG phase.  
 
78 
 
4.6 Cell Lysate Partitioning Analysis 
  
Use of purified GST-GFPuv had established that this protein is detectable by the 
Bradford assay within ATPS polymer solutions. Whilst fluorescence is useful for rapid visual 
observation, the Bradford assay is also required, since contaminating cellular proteins clearly 
cannot be detected by GFPuv fluorescence. However, purified GST-GFPuv that is already 
complexed with GSH as a result of its purification would not, therefore, be expected to interact 
strongly with added PEGylated GSH. Moreover, the point of the affinity ATPS system is to 
purify proteins directly from crude lysates. Therefore, in order to establish whether the 
PEGylated GSH conjugates could partition the GST-GFPuv fusion protein into the upper PEG 
phase of an ATPS, clarified cell lysates containing the target protein were used for evaluation 
of partitioning in ATPS. 
Specifically, a 1 ml ATPS comprising 0.5 ml each of 20% (w/v) 20000 Da PEG and 
20% (w/v) 100 kDa DEX was chosen for initial investigation, since this combination is one of 
the most consistent for lower DEX phase partitioning in the initial screening of ATPS 
combinations (Chapter 3), as well as having a lower viscosity than its higher molecular weight 
counterparts. To this was added clarified concentrated E. coli lysate (100 µl) and a 100 fold 
excess of 10 kDa PEG-GSH (section 4.2). The ATPS was then mixed by vortexing and then 
left to settle for 20 minutes and examined using UV light. Unfortunately, all detectable GST-
GFPUV fusion protein had partitioned to the lower DEX layer, rather than being “pulled” to the 
upper PEG layer by the PEGylated GSH ligand, as had been hypothesised. Further 
experiments involving a greater, 200 fold excess of 10 kDa PEG-GSH produced a similar 
result, as did repeat experiments with 5 kDa PEG-GSH. Clearly, this experimental set-up 
would not form an effective ATPS for affinity partitioning of GST fusion proteins (data not 
shown). 
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 It was hypothesised that perhaps the interactions between the high molecular weight 
DEX and the fusion protein was too great to be overcome via a PEGylated ligand and that 
therefore lower molecular weight polymer should be re-investigated. To this end, it was 
decided to test the ATPS conditions of a proven protocol described by Barbosa et al (2010), 
which had used PEGylated IDA with a coordinated cation to effect affinity purification of 
plasmid DNA, via a LacI-His6-GFPuv fusion protein. Specifically, their ATPS which produced 
the best partitioning of plasmid and protein to the upper PEG phase (which comprised 16% 
overall PEG, of which 15.85% was PEG 600 and 0.15% PEG-IDA, 14.3% DEX 40) was 
adapted for use in the current study. In this experiment, 50 µl clarified cell lysate (diluted in 50 
mM Tris pH 7.4 to 1 mg / ml total protein content) was added to PEG 600 (15.85% w/v), PEG-
GSH (0.15% w/v) and DEX 40 (14% w/v) and ultrapure water was added to a final system 
weight of 1.5 g. After mixing by vortexing and settling for 2 hrs at 30°C, fluorescence was 
examined by UV light. Unfortunately, the fluorescence of the GST-GFPuv fusion protein was 
again found in the lower DEX phase, albeit just underneath the interface of the two phases in 
both 10 kDa and 5 kDa PEG-GSH systems (data not shown).  
 To determine whether the simple addition of a higher concentration of PEG-GSH would 
result in upper PEG phase partitioning of the GST-GFPuv fusion protein, a series of ATPS 
were conducted in similar conditions to those described above.  Increased concentrations of 
the PEG-GSH ligand were used whilst maintaining an overall PEG concentration of 16% 
(Table 4.1).  
DEX 40 (%) PEG 600 (%) PEG 10000-GSH PEG 5000-GSH 
14.0 15.5 0.5  
14.0 15.0 1.0  
14.0 14.5 1.5  
14.0 14.0  2.0 
14.0 12.5  3.5 
 
Table 4.1: ATPS formed using a variety of PEG and PEG-GSH concentrations. Partitioning of GST-
GFPuv is demonstrated by green shading. 
 
Analysis showed that all ATPS had high levels of fluorescence in the lower DEX layer 
and at the interface, but not within the PEG layer.   
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4.7 Discussion 
 
The GST-GSH fusion protein purification method has been established in the research 
community for many years, having first been described by Smith, D.B. and Johnson, K.S. in 
1988. It has been a favoured protein purification method due to the high level of protein 
expression as well as the N-terminal GST moiety acting as a chaperone and therefore 
assisting the expression of the target proteins as soluble protein instead of inclusion bodies. 
In addition to these benefits, the GST fusion protein can be efficiently eluted from the GSH-
agarose using a mild, detergent free wash buffer containing reduced glutathione which does 
not denature the desired fusion. In addition to the ease of purification, there is a site-specific 
protease recognition sequence located next to the protein of interest allowing for complete 
cleavage resulting in a target protein with no additional tags (Harper, S. & Speicher, D.W., 
2011). This is particularly advantageous as tag free proteins are required for biomedical 
research and therapeutic applications. These benefits put GST-GSH affinity purification at a 
distinct advantage over other purification methodologies and therefore it was chosen as the 
initial fusion system to be studied in this project.  
SDS-PAGE was performed on the purification solution to confirm the presence of the 
GST-GFPuv fusion protein required for affinity purification within the two phase system. Figure 
4.3 shows a high concentration of fusion protein production, approximately in line with the 56 
kDa marker, allowing for a final concentration of 4.09 mg/ml. A small amount of protein 
degradation can be seen with additional bands present which are the two constituent proteins 
GFPuv and GST separately. In this methodology protease inhibitors were not utilised due to 
their toxic properties. Their use to prevent the small amount of protein degradation present 
could render the affinity ATPS method unsuitable for commercial therapeutic protein 
purification. The fusion protein obtained from this purification was used in various 
combinations of different molecular weight PEG and dextran ATPS and figure 4.4 
demonstrates the distribution of purified GST-GFPuv fusion protein within the systems. 
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Partitioning of the fusion protein into the upper PEG phase when using PEG 2000 Da indicated 
that higher molecular weight PEGs were needed to ensure that non-specific partitioning of 
proteins was not occurring. Functionalised PEG could then be used to overcome the interfacial 
tension and only partition the targeted fusion protein into the upper PEG phase. In this 
instance, PEG would be functionalised with reduced glutathione (Scheme 4.1) allowing for 
specific affinity purification of the protein fused to GST. Two functionalised PEG species (5 
kDa PEG-GSH and 10 kDa PEG-GSH) were produced and verified using 1H NMR 
Spectroscopy (Figures 4.5 and 4.6 respectively). 
The percentages of functionalised PEG described in Table 4.1 represent an 
approximate 150 to 1000 fold molar excess of PEGylated GSH over the estimated 
concentration of GST-GFPuv fusion protein. Although this high molar excess is used in column 
protein purification methods to elute the required fusion protein from the column, the 
competing GSH molecules are PEGylated so were located within the upper PEG phase. This 
should allow for all GST-GFPuv fusion proteins to partition across the interface into the upper 
PEG phase. In comparison to PEG/Salt and other solvent based ATPS systems, the interfacial 
tension present in PEG / dextran systems are very low which has traditionally been thought to 
allow for gentle partitioning of target proteins without disruption or damage occurring to the 
protein structure. (Ryden, J et al., 1971) When forming an ATPS, the concentration of the 
constituent polymers determines interfacial tension, for example – the higher the concentration 
of polymer, the higher the interfacial tension (Mittal, KL, 1981). As can be seen in Table 4.1, 
a number of different concentrations of PEG 600 were used in order to assess whether a 
reduction in interfacial tension had an effect on the partitioning of the GST-GFPuv protein. In 
this instance there was no effect and  thus unfortunately, it is clear that PEGylated glutathione 
(PEG-GSH) is unlikely to form the basis of an effective affinity ATPS for purification of fusion 
proteins. It is hypothesised that the interaction between GST and GSH is too weak to permit 
effective partitioning across the interfacial tension present between the PEG and dextran 
layers and as such, that a protein ligand interaction with a lower Kd will be required for use in 
an effective affinity ATPS for fusion protein purification (Zachariou, M. & Bailon, P., 2007). In 
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addition to this, the two proteins fused together, GST and GFPuv, are both large and carry an 
overall polar charge which may inhibit movement between the layers (Asenjo, JA et al., 2011).  
It could also be hypothesised that the act of sonication when releasing the soluble 
fusion protein from the bacterial cells may have degraded resulting in cleavage of the GST 
protein from the GFPuv protein. This would automatically prevent a proportion of GFPuv 
protein from being partitioned to the upper PEG phase. Another inhibiting factor may be steric 
hindrance caused by the sheer size of the 5 kDa and 10 kDa PEG molecules attached to the 
307 Da reduced glutathione molecule. If the PEG molecule is causing GSH to become unable 
to bind into the active site of GST, partitioning to the upper PEG phase via the affinity method 
will not occur. To this effect, further investigation will be undertaken into an alternative affinity 
ATPS model using PEGylated Nitrilotriacetic Acid (NTA) with conjugated copper ions 
alongside the addition of a small histidine tag to the target protein. This method should allow 
for the investigation of effect of binding affinities between the ligand and substrate as well as 
the size of the protein on partitioning behaviours.  
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Chapter 5. Affinity ATPS using PEGylated Copper-
Nitrilotriacetic acid (PEG-NTA-Cu2+) and Poly-Histidine (His6) 
Tagged Proteins. 
 
5.1 Introduction 
 
Studies using a GST and GSH affinity receptor and ligand complex to pull a 
protein from the DEX to the PEG phase had proved unsuccessful (Chapter 4). The 
relative weakness of the interaction between GSH and its affinity partner, GST might 
explain those results, since the Kd for the GST and GSH interaction is in the µM range.  
In contrast, that of a His6 tag / divalent cation interaction is in the nM range (Knecht et 
al., 2009). Moreover, PEGylation of the chelating ligand iminodiacetic acid (IDA) had 
previously proven successful in purifying a plasmid within an affinity ATPS system 
(Barbosa et al., 2010). It was therefore decided to attempt ATPS purification of protein 
via a His6-tag and PEGylated chelating agent. Because commercial protein purification 
resins use nitrilotriacetic acid (NTA), it was decided to PEGylate NTA and to evaluate 
PEG-NTA-Cu2+ for affinity ATPS of His-tagged protein. The synthesis of PEGylated 
NTA-Cu2+ and its evaluation in ATPS’s of both purified protein and clarified E. coli lysate 
are described.  
 
5.2 Synthesis of PEGylated NTA-Cu2+ ligands 
 
Three alternative classes of PEGylated ligands were conjugated with lysine NTA 
(2). One (methoxy PEG maleimide) (1) was obtained directly from JenKem Technology 
USA Ltd. and closely mimics the proprietary M1 PEGylation reagent provided by 
Polytherics for PEGylation of glutathione (Chapter 4) and will similarly link PEG to one 
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NTA molecule. Second and third reagents (B1 and bis-B1) were prepared according to 
the methods of Brocchini et al., (2006) and were used to link PEG to two NTA molecules 
and four NTA molecules respectively. Each reagent was used in both 5 kDa and 10 kDa 
forms of PEG.  
 
5.2.1 Preparation of methoxy PEG maleimides 
 
Both 10 kDa and 5 kDa methoxy PEG maleimide (1) were conjugated to lysine-
NTA (2) and the products purified as described (Methods 2.8.6; Scheme 5.1). The 
starting materials (1 and 2) were examined by 1H NMR spectroscopy (Figures 5.1 and 
5.2).  
 
 
Scheme 5.1: 1 Coupling of Methoxy PEG Maleimide to Lysine NTA. i – 50 mM Sodium 
Phosphate pH 6.0, 24 hrs, Room Temperature. 
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Figure 5.1: 1H NMR of Lysine NTA (2)  
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Figure 5.2: 1H NMR of Methoxy PEG Maleimide 10 kDa (1) 
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5.2.2 Preparation of B1-NTA 
 
The carboxylic DB-bis-sulfide linker (B1, obtained from Prof. Steve Brocchini, 
UCL) (5) was conjugated to both 10 kDa and 5 kDa methoxy PEG amine (4) (JenKem 
Technology USA Ltd.) and purified as described (Methods 2.8.7). The reaction scheme 
for the conjugation of mPEG B1 (6) is illustrated in Scheme 5.2. 
 
 
 
Scheme 5.2: Coupling of methoxy PEG amine (4) to B1 linker (5). i – Anhydrous 
dichloromethane under argon, room temperature, 48 hrs. 
 
The resulting conjugates were examined by 1H NMR spectroscopy (Figure 5.3) 
and then stored at -20°C under argon, until required, since the sulfide is more stable 
than the corresponding sulfone and is thus more suitable for long term storage.  
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Figure 5.3: 1H NMR Spectrum of 10 kDa PEG B1 Sulfide 
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Prior to use, the required quantity of sulfide conjugate was oxidised to the 
corresponding sulfone with Oxone® (Sigma, 228036) (Methods 2.8.8). A representative 
NMR of a sulfone product is shown in Figure 5.4. The reaction scheme for the production 
of oxidised B1 (7) is illustrated in Scheme 5.3.  
 
 
 
 
Scheme 5.3: Oxidation of PEG B1 Sulfide to Sulfone using OXONE®. i – Methanol, overnight, 
room temperature. 
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Figure 5.4: 1H NMR Spectrum of Oxidised 10 kDa PEG B1 Sulfone 
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Both 10 kDa and 5 kDa PEG B1 were conjugated to lysine-NTA and purified as 
described (Methods 2.8.9). The reaction scheme for the production of mPEG B1 lysine 
NTA is illustrated in Scheme 5.4 and the resulting conjugates were examined by 1H NMR 
spectroscopy (Figure 5.5) and then stored at -20°C under Argon, until required. 
 
 
 
 
Scheme 5.4: Conjugation of mPEG B1 to Lysine NTA. i – 20 mM Tris buffer pH 9.0, 24 hrs, 
37°C. 
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Figure 5.5: 1H NMR Spectrum of 10 kDa PEG B1 lysine NTA 
93 
 
5.2.3 Preparation of bis-B1-NTA 
 
The carboxylic DB-bis-sulfide linker (B1, obtained from Prof. Steve Brocchini, UCL) 
was conjugated to both 10 kDa and 5 kDa amine PEG amine (JenKem Technology USA Ltd.) 
and purified as described (Methods 2.8.10). The reaction scheme for the conjugation of amine 
mPEG amine to B1 is illustrated in Scheme 5.5. 
 
 
 
 
Scheme 5.5: Coupling of Amine PEG Amine to B1 linker. i – Anhydrous Dichloromethane under 
Argon, 48 hrs, room temperature. 
 
As previously, the resulting conjugates were then stored at -20°C under Argon, until 
required, since the sulfide is more stable than the corresponding sulfone and is thus more 
suitable for long term storage.  
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Prior to use, the required quantity of sulfide conjugate was oxidised to the 
corresponding sulfone with Oxone (Sigma) (Methods 2.8.11). A reaction scheme for the 
production of oxidised B1 is illustrated in Scheme 5.6.  
 
 
 
 
Scheme 5.6: Oxidation of PEG Bis-B1 Sulfide to Sulfone. i – 12 Molar equivalents OXONE, 
methanol, overnight, room temperature. 
 
Both 10 kDa and 5 kDa PEG B1 were conjugated to lysine-NTA and purified as 
previously described (Methods 2.8.12). The reaction scheme for the production of PEG bis B1 
lysine NTA is illustrated in Scheme 5.7. The resulting conjugates were then stored at -20°C 
under Argon. 
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Scheme 5.7: Conjugation of mPEG bis B1 to Lysine NTA. i – 20 mM Tris Buffer pH 9.0, 24 hrs, 
37°C.  
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5.2.4 Coordination of the Chelating Metal Ion 
 
In order for the PEGylated ligand to bind to the His6 tag it was necessary for a divalent 
cation to be coordinated using the carboxyl groups of the NTA molecule. This coordination 
was performed using copper sulphate and was achieved as described in method (2.8.13). A 
buffer with pH 4.0 was chosen as this is the pKa of the carboxyl groups of NTA producing the 
necessary reactive COO- groups via deprotonation. The coordinated copper ion and 
PEGylated lysine NTA compounds are shown in Scheme 5.8. 
 
 
 
 
Scheme 5.8: Structures showing Methoxy PEG Maleimide lysine NTA (14), mPEG B1 lysine NTA 
(15) and PEG bis B1 lysine NTA (16) with coordinated copper ions. i – 0.1 M Sodium Acetate buffer 
pH 4.0, Room Temperature, 2 hrs. 
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The resulting copper-coordinated PEG lysine NTA conjugates (5 kDa & 10 kDa mPEG 
mal lysine NTA Cu2+; 5 kDa & 10 kDa PEG B1 lysine NTA Cu2+ and 5 kDa & 10 kDa mPEG 
bis B1 lysine NTA Cu2+) were each purified away from excess uncoordinated CuSO4 using a 
PD10 desalting column into 10 mM Sodium Phosphate buffer pH 8.0 according to 
manufacturer’s instructions. 
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5.3 Preliminary ATPS formation 
 
A representative conjugate, 10 kDa mPEG B1 NTA Cu2+ (Section 5.2.4) was then 
tested in model ATPS using purified His8-tagged Interferon alpha 2a (2.5.1; His8-IFN α-2a, 
Polytherics) as a target protein. This represents a clean, model system in which the affinity 
tag is simply required to pull the target protein from the DEX phase to the PEG phase without 
potential interference from cell debris, native proteins or other biomolecules in the sample to 
be partitioned. 
In order to optimise ATPS composition, ATPS were formed according to Barbosa et al 
(2010). Using their most successful composition, a 1.5 g ATPS combining of 18% overall PEG 
600, including 12% functionalised PEG (10 kDa PEG B1 NTA Cu2+), and 14% DEX 40 was 
set up containing 50 µg purified, His8-IFN α-2a. Surprisingly, this combination did not form two 
phases. Moreover, the large quantity of functionalised PEG (1000 molar equivalents) required 
to achieve 12% modified PEG, rendered this composition impractical for scale-up. A second 
combination described by Barbosa et al (2010) comprising 16% PEG 600, including 0.15% 
functionalised PEG, 14.3% DEX 40, and 100 µg IFN α-2a was also tested, as this composition 
had previously shown the best phase partitioning for pLacI-His6-GFPuv protein. This 
combination also failed to form two distinct phases. Further examination of the protocol 
published by Barbosa et al., revealed that whilst their ATPS contained 15 mM Tris HCl pH 7.4, 
the ATPS described herein actually contained 50 mM Tris HCl pH 7.4. Although this difference 
in buffer concentration is considerable, it is perhaps surprising that it is sufficient to disrupt 
ATPS formation.  
To further investigate the influence of 50 mM Tris HCl pH 7.4, simple 20% and 10% 
PEG / DEX ATPS combinations were formed as described in Chapter 3. Two separate ATPS, 
each containing 50 µg His8-IFN α-2a were constructed with compositions of 20% PEG 20000 
/ 20% DEX 100 and 10% PEG 20000 / 10% DEX 100. In the absence of both 50 mM Tris HCl 
pH 7.4 and functionalised PEG, ATPS formed successfully in both cases. Protein 
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concentration was measured in both layers (Table 5.1, 1; 2.8.14) Fifty molar equivalents of 
functionalised PEG (10 kDa PEG B1 NTA Cu2+) were then added, the ATPS remixed and 
allowed to settle.  Protein concentration measurements were then repeated (Table 5.1, 2; 
2.8.14). Finally, Tris HCl buffer pH 7.4 was added to a concentration of 50 mM, the ATPS re-
mixed, allowed to settle and protein concentration measurements were once again taken 
(Table 5.1, 3; 2.8.14).  
 
  
The absorbance readings shown above do not indicate any partitioning to the upper 
PEG phase in either 10% or 20% ATPS combination. Upon addition of 50 molar equivalents 
of 10 kDa B1 PEG-NTA-Cu2+ an increase can be seen in the absorbance of the lower DEX 
layer indicating an increase in protein concentration. However, it was noted visually that the 
volume of the lower DEX layer had decreased due to the increased quantity of PEG in the 
system causing water movement into the upper PEG phase and therefore produced an 
increased protein concentration. Most interestingly however, the addition of 50 mM Tris HCl 
pH 7.4 to the systems caused the dissociation of Cu2+ from the NTA molecule.  This was 
observed immediately as a bright blue colour appearing just above the interface of the ATPS 
(the PEG NTA complex is normally a pale blue colour). To confirm that the copper conjugate 
is incompatible with this buffer, 50 mM Tris HCl pH 7.4 was added to the copper conjugate in 
isolation. Again, an immediate, intense bright blue colour was observed, confirming 
  10% Polymer 
Concentration 
20% Polymer 
Concentration 
  PEG 600 DEX 40 PEG 600 DEX 40 
1 
PEG / DEX ATPS with 50 
µg His8-IFN α-2a 0.036 0.125 0.045 0.087 
2 
As above, + 50 molar 
equiv.  PEG B1 NTA Cu2+  0.054 0.212 0.044 0.110 
3 
As above + Tris HCl buffer 
pH 7.4 to 50 mM 0.042 0.158 0.048 0.096 
Table 5.1: Absorbance Readings (A595) of ATPS Layers using Bradford Reagent (2.8.14) to 
Analyse Protein Concentration 
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dissociation of the copper from the functionalised PEG (data not shown). This is perhaps not 
surprising in hindsight, given the potential for Tris and NTA to hydrogen bond to each other, 
owing to their similar structures. The differing structure of IDA may explain why Tris HCl was 
an acceptable buffer in the experiments conducted by Barbosa et al., (2010). However, 
regardless of the differing concentrations of Tris buffer between the current study and that of 
Barbosa et al. (2010), it was clear that Tris would not be an acceptable buffer in an affinity 
ATPS where NTA (rather than IDA, as used by Barbosa et al) is the metal-co-ordinator. 
To determine a suitable alternative buffer, 10 mM sodium phosphate buffer pH 8.0 
(2.2.15) was added to functionalised PEG (10 kDa PEG B1 NTA Cu2+). No colour change 
resulted (data not shown) and since pH 8.0 is optimal for poly-histidine tag binding (Schmitt et 
al., 1993), 10 mM sodium phosphate buffer pH 8.0 was selected to buffer all future His-tag 
ATPS experiments.  
Interestingly, close visual investigation of the PEG 600 / DEX 40 ATPS in the absence 
of Tris buffer (Table 5.1, 1) also showed that the pale blue 10 kDa PEG B1 NTA Cu2+ complex 
partitions underneath the 600 Da PEG, just above the interface and so demonstrated a likely 
polymer gradient and suggested the need for samples to be taken from multiple positions 
within an ATPS.  
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5.4 Cell Lysate Partitioning Analysis 
 
Having developed a suitable ATPS methodology for use with NTA Cu2+ conjugates, 
attention now turned to determining whether a PEG-DEX ATPS containing functionalised, 
Cu2+ conjugated PEG could partition His6-tagged protein into the upper PEG phase. 
Accordingly, a large batch of E. coli expressing His-tagged GFPuv was prepared (2.8.2) and 
aliquoted into 50 ml samples. Cells were then harvested by centrifugation and stored frozen 
and then resuspended in 5 ml PBS containing 0.1% Triton X100 when required, to enable all 
subsequent experiments to be performed with the same batch of protein.  To estimate GFPuv 
content, a cell aliquot was lysed and its total protein content measured. His-tagged GFPuv 
was then purified from 1 ml of this aliquot and the concentration of the GFPuv measured.  As 
demonstrated in Table 5.2, GFPuv represented approximately 20% of total soluble protein.  
 
Total soluble protein 
(mg/ml) 
His6-tagged GFPuv 
(mg/ml) 
% GFPuv 
4.2 0.9 21.4 
 
Table 5.2. Protein Concentrations of Total Soluble Protein and His6-tagged GFPuv as determined 
using the Bradford Method (2.8.14). Overall percentage of His6-tagged GFPuv is also shown. 
 
It was initially anticipated that fluorescence could be used to follow GFPuv partitioning. 
Unfortunately, early observations demonstrated that Cu2+ ions quench GFPuv fluorescence 
(Lakowicz, 2006). UV-based detection of protein partitioning was therefore impossible and 
thus standard protein concentration analysis was required to detect total protein partitioning 
between the layers.  
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5.4.1 Affinity Conjugate Concentration 
 
B1 PEG-NTA-Cu2+ (10 kDa) was again selected as a representative conjugate to 
determine the effect of conjugate concentration on protein partitioning within a phosphate-
buffered ATPS, as defined in section 5.3. Both 1% and 2% concentrations of this conjugate 
were examined for their effects on protein partitioning.  Specifically, a phosphate-buffered 
ATPS with composition described by Barbosa et al. (2010) (18% (w/v) PEG 600 Da / 14% 
(w/v) DEX 40 kDa) was compared with 20% (w/v) combinations of these polymers, as 
described in Chapter 3. PEG 20000 Da was also analysed for protein partitioning as higher 
molecular weight polymers were favoured when partitioning all non-required proteins into the 
lower DEX phase (again, as determined in Chapter 3). In order to account for a possible PEG 
gradient, samples were analysed from both the top and bottom of each phase in addition to 
the interface. Owing to the large sample numbers, these experiments were analysed for 
protein concentration using the microplate method (Methods 2.8.15; Figure 5.6). 
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Figure 5.6: Total protein partitioning in ATPS, composed as labelled supplemented with 1% 10 
kDa PEG B1 NTA Cu2+ or 2% 10 kDa PEG B1 NTA Cu2+. ATPS were set up as described in methods 
(2.8.16) using 100 µl of crude cell lysate expressing his-tagged GFPuv as a test sample.  
 
 
Figure 5.6 demonstrates that 2% of the 10 kDa B1 PEG-NTA-Cu2+ conjugate was 
preferable to 1%, since the 2% concentration resulted in a wider distribution of the proteins 
between the layers of the ATPS. In contrast, 1% conjugate tended to lead to the majority of 
protein being partitioned to the PEG layer, which would preclude separation of the required, 
His-tagged protein away from other cellular proteins, since only ~20% of total; protein can be 
His-tagged GFPuv (Table 5.2).  The 2% concentration of conjugate was therefore selected for 
future study. 
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5.4.2 Analysis of 2% PEG NTA Cu2+ conjugates 
 
All six of the PEG NTA Cu2+ conjugates made in section 5.2 were tested in phosphate-
buffered ATPS to examine the protein partitioning of clarified cell lysates containing His6-
tagged green fluorescent protein (His6-GFPuv). Owing to the previous distribution of total 
proteins (Figure 5.6), both 18% PEG 600 / 14% DEX 40 and 18% PEG 20000 / 14% DEX 40 
ATPS were selected for further examination.  The 20% PEG 600 / 20% DEX 40 identified from 
Chapter 3 was not selected for further study owing to the high percentage of total protein in 
the upper PEG phase of this system (Figure 5.6) which considerably exceeds the estimated 
content of GFPuv within the total protein of the cell lysate.  Instead, Barbosa et al’s 16% PEG 
600 / 14.3% DEX 40 was selected as the third alternative ATPS. 
 
Initially, to again investigate the potential for polymer gradient formation, ATPS were 
sampled at multiple levels (Figures 5.7; 5.8; 5.9). 
 
 
Figure 5.7. Protein partitioning of Total Protein in ATPS composed of 18% PEG 600 / 14% DEX 
40 with 2% of overall PEG being functionalised (PEG-NTA-Cu2+) as described. 5 µl samples were 
taken from both the top and bottom of the PEG and DEX phases along with a sample from the interface. 
These were analysed using the microplate Bradford assay as described in method 2.8.15. 
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Figure 5.8. Protein partitioning of Total Protein in ATPS composed of 16% PEG 600 / 14.3% DEX 
40 with 2% of overall PEG being functionalised (PEG-NTA-Cu2+) as described. 5 µl samples were 
taken from both the top and bottom of the PEG and DEX phases along with a sample from the interface. 
These were analysed using the microplate Bradford assay as described in method 2.8.15. 
 
 
 
Figure 5.9. Protein partitioning of Total Protein in ATPS composed of 18% PEG 20000 / 14% DEX 
40 with 2% of overall PEG being functionalised (PEG-NTA-Cu2+) as described. 5 µl samples were 
taken from both the top and bottom of the PEG and DEX phases along with a sample from the interface. 
These were analysed using the microplate Bradford assay as described in method 2.8.15. 
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Examination of Figures 5.7, 5.8 and 5.9 demonstrate no clear trends. Therefore total 
protein concentrations in the PEG, DEX and interface layers were summed and examined 
graphically (Figure 5.10; 5.11; 5.12). 
 
 
 
Figure 5.10. Protein partitioning of Total Protein in ATPS composed of 18% PEG 600 / 14% DEX 
40 with 2% of overall PEG being functionalised (PEG-NTA-Cu2+) as described. 5 µl samples were 
taken from both the top and bottom of the PEG and DEX phases along with a sample from the interface. 
These were analysed using the microplate Bradford assay as described in method 2.8.15. Percentage 
values of total protein in the upper and lower of each phase were combined to show an overview of 
protein distribution.  
 
Examination of Figure 5.10 shows a trend towards a spread of protein over both PEG 
and DEX layers as well as at the interface. As approximately 20% of overall protein is His6-
tagged GFPuv all 18% PEG 600 / 14% DEX 40 ATPS, with the exception of the system 
containing 10 kDa M1 PEG-NTA-Cu2+, demonstrated non-specific partitioning of protein into 
the PEG phase. The system containing 10 kDa M1 PEG-NTA-Cu2+ demonstrated a total 
protein partitioning in the PEG phase of 23%, and whilst this is still a couple of percent higher 
than the approximate GFPuv content, this system was closest to the required partitioning 
profile suggesting that further analysis of the proteins in each layer was required (Figure 5.14).  
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A secondary trend noticeable within this figure is an increase in protein partitioning at 
the interface and a reduction of protein within the DEX phase when the functionalised PEG 
used is 10 kDa B1 PEG-NTA-Cu2+, 5 kDa bis-B1 PEG-NTA-Cu2+ and 10 kDa bis-B1 PEG-
NTA-Cu2+.  
 
 
Figure 5.11. Protein partitioning of Total Protein in ATPS composed of 16% PEG 600 / 14.3% DEX 
40 with 2% of overall PEG being functionalised (PEG-NTA-Cu2+) as described. 5 µl samples were 
taken from both the top and bottom of the PEG and DEX phases along with a sample from the interface. 
These were analysed using the microplate Bradford assay as described in method 2.8.15. Percentage 
values of total protein in the upper and lower of each phase were combined to show an overview of 
protein distribution. 
 
Examination of Figure 5.11 shows a high level of protein partitioning to the lower DEX 
phase in all ATPS formed, especially within those ATPS formed with 5 kDa and 10 kDa M1 
PEG-NTA-Cu2+. These two ATPS show low levels of protein partitioning to the upper PEG 
phase, 17% and 13% respectively, with the remaining systems demonstrating protein 
partitioning higher than the available ~20% His6-tagged GFPuv. These values suggest that 
there is non-specific binding and partitioning occurring to the PEG phase. The system formed 
using 5 kDa M1 PEG-NTA-Cu2+ was selected for further protein analysis by SDS-PAGE 
(Figure 5.15) as the percentage protein partitioned to the PEG phase was close to the His6-
tagged GFPuv cleared cell lysate content. 
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Figure 5.12. Protein partitioning of Total Protein in ATPS composed of 18% PEG 20000 / 14% 
DEX 40 with 2% of overall PEG being functionalised (PEG-NTA-Cu2+) as described. 5 µl samples 
were taken from both the top and bottom of the PEG and DEX phases along with a sample from the 
interface. These were analysed using the microplate Bradford assay as described in method 2.8.15. 
Percentage values of total protein in the upper and lower of each phase were combined to show an 
overview of protein distribution. 
 
As in Figure 5.10, Figure 5.12 also shows a trend towards a spread of protein 
partitioning across the layers. However, in contrast to Figure 5.10, these ATPS combinations 
of 18% PEG 20000 / 14% DEX 40 with 2% functionalised PEG demonstrate protein 
partitioning predominantly to the DEX phase with greater than 50% of total protein in the DEX 
layer of all ATPS rising to almost 80% when using 5 kDa bis-B1 PEG-NTA-Cu2+ and almost 
90% of total protein when using 10 kDa bis-B1 PEG-NTA-Cu2+. Correspondingly, there is also 
a large decrease in protein partitioning to the PEG phase when this rise in partitioning to the 
DEX phase is seen.  
When considering the His6-tagged GFPuv content of overall protein is approximately 
20%, it is interesting to note the protein contents within PEG layers of ATPS formed with 5 
kDa M1 PEG-NTA-Cu2+, 5 kDa B1 PEG-NTA-Cu2+ and 10 kDa B1 PEG-NTA-Cu2+ are 27%, 
26% and 28% respectively. These ATPS were also selected for further protein analysis by 
SDS-PAGE (Figures 5.13 and 5.15).  
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Figure 5.13. SDS-PAGE of Protein Content within ATPS Layers from 18% PEG 600 / 14% DEX 40 
with 2% 10 kDa B1 PEG-NTA-Cu2+ and 18% PEG 600 / 14% DEX 40 with 2% 5 kDa B1 PEG-NTA-
Cu2+ Systems. The gel was prepared and run as described in methods 2.6.2 with 20 µl of sample 
loaded into each well. The gel was stained using Coomassie Brilliant Blue.His6-tagged GFPuv (~ 27 
kDa) is shown as a dense band. Lane 1 – 5 µl PageRuler™ Prestained Protein Ladder (Thermo 
Scientific); Lanes 2 – 5 – ATPS 18% PEG 600 / 14% DEX 40 with 2% 10 kDa B1 PEG-NTA-Cu2+; 2 – 
Upper PEG Phase, 3 – Lower PEG Phase, 4 – Upper DEX Phase, 5 – Lower DEX Phase; Lanes 6 – 9 
– ATPS 18% PEG 600 / 14% DEX 40 with 2% 5 kDa B1 PEG-NTA-Cu2+; 6 – Upper PEG Phase, 7 – 
Lower PEG Phase, 8 – Upper DEX Phase, 9 – Lower DEX Phase. 
 
Figure 5.13 above shows His6-tagged GFPuv (indicated by the dark bands at 
approximately 25 kDa) spread across both layers with soluble native proteins also present in 
both layers. The bands representing soluble native proteins are not as distinctive and can be 
described as a smear which appears darker when more protein is present in the sample. In 
both ATPS, a greater concentration of protein can be seen in the DEX samples than PEG 
samples but there is still contamination of native cellular proteins in the phase.   
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Figure 5.14. SDS-PAGE of Protein Content within ATPS Layers from ATPS 18% PEG 20000 / 14% 
DEX 40 with 2% 10 kDa M1 PEG-NTA-Cu2+Systems. The gel was prepared and run as described in 
methods 2.6.2 with 20 µl of sample loaded into each well. The gel was stained using Coomassie Brilliant 
Blue. Lane 1 – 5 µl PageRuler™ Prestained Protein Ladder (Thermo Scientific); Lanes 2 – 5 – ATPS 
18% PEG 20000 / 14% DEX 40 with 2% 10 kDa M1 PEG-NTA-Cu2+; 2 – Upper PEG Phase, 3 – Lower 
PEG Phase, 4 – Upper DEX Phase, 5 – Lower DEX Phase. 
 
As in Figure 5.13, His6-tagged GFPuv can be seen in all four samples from the ATPS 
indicating a spread across both the PEG and DEX layers. However, in contrast with Figure 
5.13, there are only two contaminating bands present in lane 2 from the native soluble proteins 
of E.coli expression cells in the upper part of the PEG phase. Lane 3 shows slightly more 
contamination of native proteins in the lower part of the PEG layer of this ATPS. Thus, although 
the yield of His6-tagged GFPuv in the upper PEG phase is comparatively poor, relatively good 
purification has been obtained in this sample.   
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Figure 5.15. SDS-PAGE of Protein Content within ATPS Layers from ATPS 18% PEG 20000 / 14% 
DEX 40 with 2% 5 kDa M1 PEG-NTA-Cu2+ and ATPS 16% PEG 600 / 14.3% DEX 40 with 2% 5 kDa 
M1 PEG-NTA-Cu2+Systems. The gel was prepared and run as described in methods 2.6.2 with 20 µl 
of sample loaded into each well. The gel was stained using Coomassie Brilliant Blue. Arrow indicates 
His6-tagged GFPuv. Lanes 1 & 2 – 5 µl PageRuler™ Prestained Protein Ladder (Thermo Scientific) & 
overflow; Lanes 3 – 6 – ATPS 18% PEG 20000 / 14% DEX 40 with 2% 5 kDa M1 PEG-NTA-Cu2+; 3 – 
Upper PEG Phase, 4 – Lower PEG Phase, 5 – Upper DEX Phase, 6 – Lower DEX Phase; Lanes 7 – 
10 – ATPS 16% PEG 600 / 14.3% DEX 40 with 2% 5 kDa M1 PEG-NTA-Cu2+; 7 – Upper PEG Phase, 
8 – Lower PEG Phase, 9 – Upper DEX Phase, 10 – Lower DEX Phase. 
 
 Examination of Figure 5.15 also demonstrates a spread of His6-tagged GFPuv across 
all layers in both ATPS described. It is noticable that the system comprising 16% PEG 600 / 
14.3% DEX 40 with 2% 5 kDa M1 PEG-NTA-Cu2+ (lanes 7 – 10) partitions the majority of total 
protein content to the DEX layer. In contrast, there is a greater degree of  His6-tagged GFPuv 
partitioning into the PEG phase of the ATPS shown in lanes 3 – 6 (18% PEG 20000 / 14% 
DEX 40 with 2% 5 kDa M1 PEG-NTA-Cu2+).  
Similarly to Figure 5.14,  the presence of native soluble proteins is far reduced in the 
PEG phase but not totally eliminated. Only two contaminant protein bands are present in the 
PEG phase of these two ATPS (lanes 3, 4, 7 and 8; Figure 5.15), and the relative intensity of 
these contaminant bands in comparison to His6-tagged GFPuv is low.   
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5.5 Discussion 
 
 In section 5.3 it was determined that Tris buffer was an unsuitable buffer to use for 
affinity ATPS with PEGylated NTA compounds with coordinated copper ions as demonstrated 
in table 5.1 where the addition of Tris buffer caused the dissociation of coordinated copper 
ions. This is due to Tris being similar in structure to NTA but as Tris has a pKa of 8.07, close 
to the pH of the buffer, the carboxyl groups will be deprotonated and therefore compete with 
the NTA to coordinate the copper ions. To avoid dissociation of the copper ion, a phosphate 
buffer (pH 8.0) was selected for use in further experiments within this chapter. 
 The results in section 5.4.1 indicate that a 2% concentration of functionalised PEG was 
preferable over 1% functionalised PEG as the ATPS containing 2% concentration of 
functionalised PEG demonstrated a spread of proteins over the two layers (Figure 5.6). This 
was beneficial in comparison to 1% functionalised PEG concentration as these systems 
partitioned the majority of proteins to the PEG phase. These results were subsequently carried 
through into the experiments performed in section 5.4.2.  
Successful development of an affinity ATPS would be indicated by partitioning of the 
protein of interest to the PEG phase using the PEGylated NTA-Cu2+ affinity conjugates. This 
goal has been partially achieved. Purification is always a balance of purity of individual 
fractions against yield of the required protein. Whilst yield is poor (the results in this section 
showed that the His6-tagged GFPuv was spread across both of the layers within all of the 
ATPS tested- see figures 5.7, 5.8 and 5.9), the purity is relatively good in all or part of the PEG 
phase of three ATPS tested (16% PEG 600 / 14.3% DEX 40 with 2% 5 kDa M1 PEG-NTA-
Cu2+ shown in figure 5.15, 18% PEG 20000 / 14% DEX 40 with 2% 5 kDa M1 PEG-NTA-Cu2+ 
shown in figure 5.15 and 18% PEG 20000 / 14% DEX 40 with 2% 10 kDa M1 PEG-NTA-Cu2+ 
shown in figure 5.14) with only two minor contaminants detectable by SDS-PAGE (Section 
5.4).  
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Whilst the ATPS comprising 16% PEG 600 / 14.3% DEX 40 with 2% 5 kDa M1 PEG-NTA-
Cu2+ (Figure 5.15) produced a relatively clean separation of His6-tagged GFPuv into the PEG 
phase, the yield of protein was very low in this system. In contrast, the ATPS comprised of 
18% PEG 20000 / 14% DEX 40 with 2% 10 kDa M1 PEG-NTA-Cu2+ demonstrated a higher 
yield of required protein, again with only two contaminating proteins in the upper part of the 
PEG phase. A similar yield of protein was obtained with the ATPS comprising 18% PEG 20000 
/ 14% DEX 40 with 2% 5 kDa M1 PEG-NTA-Cu2+, in this case, with purity being maintained 
throughout the whole PEG phase. 
 When investigating which metal ion to use for the purification of a therapeutic protein, 
it was prudent to identify which metal ions would pose a risk to the patient if contamination 
occurred during the production process. The European Medicines Agency (EMA) have three 
classifications of metal ranging from class one – a significant safety concern to class three – 
minimal safety concern with class two being a low safety concern. Copper was chosen for this 
methodology as it is in class two and therefore has a lower safety concern when administered 
to the body in comparison to the class one significant safety concern associated with nickel, 
the other commonly used ion in metal ion affinity chromatography (European Medicines 
Agency, 2007). Copper has been assigned class two status as it is a functional component of 
cuproenzymes for example cytochrome c oxidase and ascorbic acid oxidase as well as playing 
a key role in the scavenging of radicals in the body reducing oxidative stress (Stanstead, HH., 
1995). According the guidelines released by the EMA in 2007, oral exposure to copper is 
limited to 2500 µg / day and a concentration of 250 ppm. Parenteral exposure to copper has 
a reduced limit 250 µg / day and a concentration of 25 ppm. When following good 
manufacturing practice, levels of excess copper ions should be kept to a minimum via the use 
of filtration methods isolating the free copper ions away from the functionalised PEG with 
conjugated metal ions. It is however noted that a concentration of less than 5 ppm in an 
administered medicine is unlikely to cause an allergic response even in highly sensitive 
patients (Uter et al., 1995) 
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 Due to the high costs of therapeutic protein production it is advantageous to keep costs 
to a minimum especially when considering the scaling up of a method to industrial levels. An 
advantage of using copper ions conjugated to functionalised PEG when compared to the 
previous protein fusion methods is the ability to reuse the copper bound functionalised PEG 
as well as recycling any filtered, unbound copper to freshly prepared PEG-NTA conjugates. 
This ability to reuse and recycle any unbound copper would allow for an initially expensive 
component to develop a lower cost per use. 
 
115 
 
Chapter 6. Conclusion 
 
The initial study was performed with a systematic approach in order to determine which 
w/v concentrations of polymer molecular weights formed two distinct phases, and the optimal 
conditions for this to happen. This was due to the mechanisms for partitioning not currently 
being understood in the literature. The present systematic review of the literature identified 
that the following gaps in knowledge required further attention: the need for additional research 
into the exact mechanisms and influences on protein partitioning as well as the development 
of a large scale purification process from lab bench scale. The selection of PEG and Dextran 
have therefore provided the most comprehensive information about separation to date and 
provide the most suitable materials to effect the most efficient separation when considering 
yield, cost and purity. 
When the present study examined specifically PEG & Dextran combinations in chapter 
3, it was evident that when the 10% w/v polymer concentrations were combined only 10 ATPS 
were formed compared to 25 ATPS when formed using 25% w/v concentrations (Table 3.1). 
Due to the high viscosity of the 25% w/v polymer, particularly the dextran solutions, it was 
difficult to accurately pipette the required volume. It was therefore decided that a lower 
concentration, 20% w/v, would be used as this would maintain the high occurrence of ATPS 
formation. An advantage to using a simple 20% w/v polymer solution would have been easily 
and quickly produced in a laboratory or industrial scale with minimal measuring although 
having an increased cost due to quantities of polymer being used. Should this method have 
worked, this would have been a distinct advantage of using affinity ATPS as a generic affinity 
protein purification system through not only ease of use, but the potential for the production of 
a high purity protein.   
As previously discussed in section 5.5 it is essential to have a high purity within 
medicines to avoid any unwanted side effects or reactions. Whilst some medicines need to be 
highly pure, such as those delivered intravenously (for example - intravenous nutrition) with 
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subcutaneous injectable medicines having a slightly higher level of impurity tolerance (e.g. – 
insulin), whilst some medicines can have a higher tolerance of impurities such as those 
delivered orally. Whilst orally administered drugs can have a higher impurity tolerance, the 
dosages have to be higher due to the process of digestion occurring in the stomach and 
intestines before a proportion of the drug can be absorbed. An advantage to administering 
therapeutic proteins parenterally is an increased efficacy of the protein as it will not be digested 
in the digestive system but the purity of the end product will have to be much higher to gain 
EMA/FDA approval. There does, however, need to be additional consideration for any 
impurities that may cause an anaphylactic response, such as nut allergies that can be 
triggered from contamination on a production line. In this instance, it was determined that the 
level of contamination from copper ions would be unlikely to trigger an anaphylactic response 
as long as the levels were lower than 5 ppm (Uter et al., 1995).  
The use of PEG and dextran in this study have the obvious advantage that any trivial degree 
of contamination by these two polymers can be dealt with by the body. This is demonstrated 
by the regular use of PEG as a bio conjugate to improve the in vivo circulation half-life of the 
drug through reducing urinary excretion of the molecule (Yang et al., 2004) as well as enabling 
reduced dosages to be administered (Alconcel, S., et al, 2011). In order to remove PEG from 
the body it is metabolised via oxidation of the alcohol groups to form a carboxylic acid, usually 
performed by alcohol dehydrogenase enzymes (Herold et al., 1989). PEG metabolism also 
appears to be driven by molecular weight with a higher proportion of small molecular weight 
polymers (less than 5000 Da) being metabolised (Schaffer et al., 1950). In contrast, larger 
molecular weight PEG polymers (above 5000 Da) tend to be removed by biliary elimination 
(Friman et al., 1993, Webster et al., 2007). Dextran is also regularly used within medicine as 
a volume expander when hypovolemic shock is occurring. As dextran is simply a polymer 
constructed of glucose monomer units, the body can easily handle and digest the polymer, via 
glucosidases, and utilise it for normal bodily processes such as respiration. The 
biocompatibility of dextran is of particular importance for future development of this method as 
a second ATPS could be used alongside a PEGylated protease to cleave the target 
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therapeutic protein from the histidine tag and metal ion complex. This cleaved target protein 
would then settle into the lower dextran layer and would not require further purification for use.  
 To ensure that the analysis of protein concentration in the different ATPS layers was 
reliable, it was important to determine whether the presence of PEG or dextran would affect a 
Bradford assay (section 3.3). Figure 3.1 and table 3.2 both demonstrated that the presence of 
polymer molecules produced a negligible effect as supported by Barbosa et al., 2009. The 
Bradford assay was therefore considered suitable for use in future ATPS protein concentration 
analysis. This is advantageous for future development of the method as the Bradford assay is 
a well-established and industrially recognised method of protein quantification.  
Before the addition of cell lysate or purified protein to the 20% w/v polymer solutions 
20 ATPS were formed when left to settle. There was shown to be a material effect on ATPS 
formation by the addition of cell lysate or purified protein as the number of ATPS formed was 
reduced to just 15 systems. This could be due to the addition of 100 µl of H2O therefore 
adjusting the overall polymer concentrations and therefore water densities of the two layers. 
The change in ATPS formation could also be due to the surface properties of any proteins or 
cellular material being added interacting with the polymers and therefore reducing the 
interactions between polymer and H2O (Israelachvili, J., 1997). 
There was also a small difference noted in the number of ATPS that were formed when 
either settled or centrifuged with cell lysate or purified protein. When left to settle 15 ATPS 
formed compared to 14 when formed by centrifugation (Table 3.3). Although this difference is 
not large it does indicate that there is more efficient polymer separation when left to settle for 
30 minutes. When considering the scale up of the system to potentially hundreds of litres on 
an industrial scale, allowing the systems to settle would be advantageous compared to 
centrifugation as larger batches could be processed when settling allowing for faster 
processing and a potential reduction in costs due to not needing expensive large scale 
centrifugation equipment.  
 As the proteins are being produced by bacteria and purified away from the complete 
bacterial cell contents there will be other biopolymers present such as DNA as well as proteins. 
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It was appropriate to also test the partitioning of genomic material to ensure that it wouldn’t 
contaminate the target therapeutic protein. The 20% w/v ATPS were then further tested to 
determine which systems demonstrated complete protein and genomic DNA partitioning to 
the lower dextran phase as this is a necessity for the further development of the ATPS as a 
generic affinity peptide purification system. It was found that the combination of higher 
molecular weight PEG and Dextran were the most successful when formed both by being left 
to settle and being centrifuged (Figure 3.3). This is thought to be due to there being a greater 
difference in the water density produced in each layer as the increased size of the polymer 
exhibits greater solvent ordering properties than their lower molecular weight counterparts 
(Zaslavsky, B. 1995). It has also been shown that both PEG and DEX are monopolar Lewis 
bases which means, when hydrogen bonding and Lifshitz-van der Waals interactions are 
considered, they will both repel each other strongly when immersed in water. This repulsion 
energy can be further increased with an increase in the molecular weight of the polymer 
explaining why the higher concentration polymer solutions as well as the higher molecular 
weight polymer solutions preferentially formed two distinct phases (Van Oss, C.J. et al., 2011).  
The partitioning of the genomic DNA was also analysed from the systems that were 
prepared using GFPuv in cell lysates and was seen to separate to the lower dextran layer in 
all formed ATPS when both formed by the centrifugation method and the settling method 
(Figure 3.4). This is due to the dextran layer having a more water rich and therefore polar 
environment for the DNA. It was also observed that there was a greater tendency for protein 
partitioning to the lower dextran phase in the presence of the cell lysate, whether the ATPS 
was formed by settling or centrifugation. 
When examining the protein partitioning behaviours it was established that leaving the 
systems to settle was much more effective than centrifugation when full protein partitioning 
into the lower dextran layer was required. This could be because the act of leaving the layers 
to form naturally allowed the proteins to interact with the environment for a longer period of 
time and therefore partitioning into their optimal environment; compared to the centrifugation 
method which forced the separation of the polymers but tended to result in a spread of the 
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protein across the two phases. Such mixed partitioning is thought to be due to the surface 
charge of the proteins interacting with both of the polymers but possibly not having time to 
settle into the desired phase. This is especially thought to be the case as this was 
predominantly seen in systems that were used to separate purified GFPuv which has a 
polyhistidine tag (Figure 3.5). The presence of this tag causes the protein to be approximately 
1 kDa larger than the wild type GFPuv and also contributes to the overall charge of the protein 
due to its imidazole groups and therefore may cause there to be a difference in the partitioning 
behaviours (Fan, W. 1997). 
The ATPS that look most promising for future studies are the settled ATPS that 
partitioned both cell lysates and purified GFPuv to the lower dextran layer. There are four 
systems that will be used consisting of PEG 4000 / Dextran 40, PEG 20000 / Dextran 40, PEG 
20000 / Dextran 100 and PEG 20000 / Dextran 200. These selected systems look the most 
promising, as it is necessary for all contents of the cell lysate to remain in the dextran layer 
(Figure 4.4), as well as utilising the higher molecular weight polymers as previously suggested 
by Van Oss, C.J. et al., (1987). This will then allow the PEGylated GSH (of which PEGylation 
has previously been shown to influence the partitioning of a molecule to the PEG layer 
(Barbosa et al., 2010)) to drag the GST tagged peptide into the upper PEG layer. PEG-GSH 
did however prove unsuccessful as an affinity partner within ATPS (Table 4.1) as it is thought 
the binding affinity between the receptor and ligand was not strong enough to overcome the 
interfacial tension present.  
To overcome the interfacial tension, PEGylated NTA with a coordinated metal ion, in 
this case copper, was selected as research suggested a higher binding affinity between a 
coordinated metal ion and polyhistidine tagged proteins. Copper was selected after careful 
consideration as it has a lower risk level when consumed or injected compared to nickel which 
is commonly used in metal ion affinity protein purification. The European Medicines Agency 
(EMA) in 2007 recommended that copper, as a class two metal, demonstrates a low safety 
concern due to its requirement in dietary forms for a number of biological processes 
(Stanstead, HH., 1995). If the therapeutic protein is to be administered orally then the 
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tolerance for contaminating copper is 2500 µg/day compared to a tolerance level of 250 µg/day 
however the dosage required for parenterally administered therapeutic protein would be far 
lower. These experiments were performed initially with a Tris buffer, as previously performed 
by Barbosa, H. et al., 2009, that proved unsuitable due to its ability to disassociate the metal 
ion from NTA at pH 7.4 (Table 5.1). A more suitable phosphate buffer was selected at pH 8.0, 
a pH where the interaction between metal ions and polyhistidine tags is reported to be 
strongest. Barbosa would not have encountered the same unsuitability due to using IDA which 
has a structure distinct to that of Tris and NTA. 
Three Af-ATPS have been identified that successfully partition His6-tagged GFPuv into 
the PEG phase via the affinity ligands 5 kDa M1 PEG-NTA-Cu2+ and 10 kDa M1 PEG-NTA-
Cu2+, albeit with a relatively low yield (Figures 5.13 and 5.14). Of these, 18% PEG 20000 / 
14% DEX 40 with 10 kDa M1 PEG-NTA-Cu2+ (Figure 5.14) has the best potential for future 
use since purity is maintained throughout the entire PEG phase with a relatively high yield of 
protein. The protein yield and purity is of great importance when producing a therapeutic 
protein. As previously discussed, a protein administered as a drug must be free from impurities 
or within prescribed limits as described with free copper ions. If a high protein purity can be 
obtained, then little to no further processing would be required once collected in the dextran 
layer of the second shake. This is highly advantageous in a commercial environment as 
downstream processing costs would be vastly reduced with a reduction in processing steps.  
Future work could investigate the effect of pH on this optimal system. As E.coli contains 
a number of native proteins that can bind to NTA resin (binding buffers are pH 8.0) it seems 
reasonable to assume that these proteins may also bind to the PEGylated NTA ligands used 
in the current study. It is thought that using a binding buffer at pH 8.0 deprotonates the external 
histidine residues present on native cellular proteins, which in turn leads to their co-purification 
via NTA ligands. Therefore it may be possible to reduce or eliminate the binding of these native 
proteins by slightly reducing the pH of the buffer systems used, such that His6-tags remain 
deprotonated, whilst the individual residues on the surface of native proteins become 
protonated and so lose their affinity for the PEGylated ligands described herein. The reduction 
121 
 
of non-specific binding to the PEGylated NTA ligands would elevate commercial appeal of this 
purification method, particularly at laboratory bench scale. After consideration of the 
techniques used, a combination of the ability to filter and reuse any free copper ions as well 
as settling the systems instead of using centrifugation lend this method to being scaled up to 
commercial levels. Costs should also be considered, so fine-tuning the methodology to use 
lower concentrations of PEG and dextran would make the purification technique industrially 
appealing. The proposed mechanism of using a PEGylated protease to cleave the therapeutic 
protein directly from the histidine tag in order to be removed in the lower dextran layer of a 
secondary ATPS would add additional costs but the final product would be simply the target 
therapeutic protein, without any additional amino acids which can prove essential for FDA / 
EMA approval, located within a biocompatible polymer solution. A further consideration would 
be when working with temperature sensitive proteins. In this study, ATPS were difficult to 
repeatedly produce at 4 °C due to the increased viscosity of the polymers and therefore 
currently recommended for therapeutic proteins that are stable at room temperature. 
Overall this thesis has provided evidence that ATPS purification of therapeutic proteins 
is possible when using an 18% PEG 20000 / 14% DEX 40 system containing 10 kDa M1 PEG-
NTA-Cu2+. This system allowed for a relatively high yield and purity of the desired therapeutic 
protein into the upper PEG phase when allowed to settle at room temperature. The 
practicalities of this methodology have been explored and discussed, particularly with regard 
to technical achievability, yield, cost effectiveness and purity. It is suggested that for 
therapeutic proteins to be delivered parenterally, the yield can be sacrificed slightly in order to 
obtain a higher purity. Conversely, for orally administered drugs a medium purity, larger scale 
process could be employed.  
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